CONFIDENTIAL –FOIA Exemptions Apply in U.S. 1
Status: Approved ,  Date: 20 April 2021Janssen Research & Development *
Clinical Protocol
A Multi -center, Open- label, Single -arm Phase 2 Study  of the Adjuvant Treatment of 
Apalutamide and Androgen Deprivation Therap y (ADT) in Treatment- naïve Participants Who 
Have Undergone Radical Prostatectomy  (RP) for Non- metastatic Prostate Cancer andWho Are 
atHigh Risk for Metastases
Protocol 56021927PCR2041; Phase 2
AMENDMENT 2
JNJ-56021927 (apalutamide)
*Janssen Research & Development is a global organization that operates through different legal entities in
various countries. Therefore, the legal entity acting as the sponsor for Janssen Research & Development
studies may vary, such as, but not limited to Janssen Biotech, Inc.; Janssen Products, LP; Janssen
Biologics, BV; Janssen -Cilag International NV; Janssen, Inc; Janssen Pharmaceutica NV; Janssen
Sciences Ireland UC; Janssen Biopharma Inc.; or Janssen Research & Develo pment, LLC. The term
“sponsor” is used throughout the protocol to represent these various legal entities; the sponsor is
identified on the Contact Information page that accompanies the protocol .
IND: 104676
Status: Approved
Date: 20 April 2021
Prepared by: Janssen Research & Development, LLC; Janssen Research & Development, a division 
of Janssen Pharmaceutica NV
EDMS number: EDMS
-ERI-203744111, 3.0
GCP Compliance: This study will be conducted in compliance with Good Clinical Practice, and applicable regulatory 
requirements. 
Confidentiality Statement
The information provided herein contains Company trade secrets, commercial or financial information that the Company 
customarily holds close and treats as confidential.  The information is being pr ovided under the assurance that the recipient 
will maintain the confidentiality of the information under applicable statutes, regulations, rules, protective orders or 
otherwise .
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 2
Status: Approved ,  Date: 20 April 2021PROTOCOL A MENDMENT S UMMA RY OF CHA NGES TA BLE
DOCUMENT HISTORY
Document Date
Amendment 2 20-Apr-2021
Amendment 1 12-Aug-2020
Original Protocol 14-May-2020
Amendment 2 ( 20-April-2021 )
Overall Rationale for the Amendment: The main reason for the amendment is to add a sub-study to assess 
testosterone dynamics when relugolix is administered concurrently with apalutamide. Other clarifications 
to the main study have also been made.
Section number
and Nam eDescription of Change Brief Rationale
1.1 Synopsis The rationale for sub -study is added. To add the details of sub -study.
1.1 Synopsis 
Overall Design ;
1.2 Schema ;
4.1 Overall Design 
of Main Study
5.1 Inclusion 
Criteria 3 ;
5 Study Population
6.1 Study 
Intervention 
AdministeredThe maximum duration from post radical 
prostatectomy (RP) to start of study intervention or 
enrol lment in the study i s updated from 60 days to 
betw een Day 29 and Day 90 post -RP.
Screening duration is changed from 60 to 90 days 
before administration of the study intervention.
The w indow for initiation of study intervention 
was updated as betw een Day 29 and Day 90 
post-RP.To reflect the practices where 
patients may be seen later after 
surgery and to provide additional 
clarification in other sections due to 
updated eligibility criteria.
1.1 Synopsis 
Number of 
ParticipantsFollow ing sentence was added: The sub -study 
consisting of 12 partic ipants will be in addition to 
the 94 main ApaRP protocol participants and 
statistical analyses will be performed separately.
Upon completion of the sub -study, participants will 
be transitioned into the main study beginning at 
Cycle 2 Day 1.To add the details of sub -study.
1.1 Synopsis 
Biomarker 
Evaluations ;
1.3 Schedule of 
Events and footnote 
j;
4.1 Overall Design 
of Main Study
8.6 BiomarkersRPtissue analysis results may be utilized in 
addition to the primary biopsy and sent to 
sponsor’s laboratory partner.To clarify the w ordings related to 
biomarker collection as in some 
cases RP tissue may be used.
1.2 Schema ;
5.1 Inclusion 
Criteria 5Definition of high -risk population is updated . T o clarify that high risk can be 
determined from RP pathology 
report in addition to biopsy 
as in some cases only RP tissue 
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 3
Status: Approved ,  Date: 20 April 2021may be available or may more 
accurately reflect the disease state.
1.3 Schedule of 
EventsPost-operative PSA evaluation at screening was 
separated from PSA evaluation forefficacy .To separate scr eening evaluation 
from efficacy evaluation.
1.1 Synopsis 
Overall Design;
4.1 Overall Design 
of the Main StudyThe evaluation standards for patients under 
androgen deprivation were added.To meet current standards for 
patients under androgen 
deprivation.
5.1 Inclusion 
Criteria 4Follow ing words in bold w ere added: have 
recovered from RP procedure and have had no 
worsening in cardiac risk in the peri -operative 
period per the clinical judgment of the 
investigator .To ensure reassessment of 
cardiovascular risk prior to 
reinitiating study intervention after 
surgery .
1.3 Schedule of 
Events footnote g
8.2.1 Physical 
examinationsFollow ing sentence was added for focused physical 
examination: Any new complaints, symptoms 
reported by participants or adverse events noted by 
providers should guide the need and extent of 
physical examination.To provide clarity on focused 
physical examination .
1.2 Schema;
4.1 Overall Design 
of Main Study
8 Study 
Assessments and 
Procedures“Main study” was added to the sub -section 
heading.
It was clarified that blood volume mentioned is for 
main study.To differentiate the main study 
from sub -study .
5.2 Exclusion 
Criteria 8It was specified that malignancies considered cured 
for more than 24 months are allow ed. To allow  participants cured for 
more than 24 months to enroll in 
the study.
5.2 Exclusion 
Criteria 9Duration of cardiac abnormalities prior to baseline 
changed from 6months to 12 months.To comply with the new guidance 
from other registrational studies for 
peri-operative use of apalutamide in 
clinical trials
8.6 Biomarkers Follow ing sentence was added: Biopsy tissue is 
required for risk scores (Prolaris) and is pre ferred 
for HRD testingTo clarify type of tissue required 
for biomarker collection.
10.13 Appendix 13 Description of sub -study protocol, including 
rationale, schema, endpoints, and schedule of 
activities was added.Study testosterone dynamics of 
novel oral hormonal agent relugolix 
when administered concurrently 
with apalutamide.
10.14 Appendix 14 New  Appendix with detailed information of 
sub-study pill diary was added .To provide the details of the pill 
dairy required for the sub -study .
10.15 Appendix 15 Amendment summary table for Amendment 1 w as 
moved to Appendix 15.The older amendment is moved to 
the appendix.
References New  references were added. To provide references for new text. 
Throughout protocol Minor grammatical, spelling, and formatting
changes are made.Minor errors w ere noted.
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 4
Status: Approved ,  Date: 20 April 2021TABLE OF CONTENTS
PROTOCOL A MENDMENT S UMM ARY OF CHA NGES T ABLE ............................................................... 2
TABLE OF CONTENTS ............................................................................................................................... 4
LIST OF IN -TEXT T ABLES A ND FIGURES ................................................................................................ 7
1. PROTOCOL SUMMA RY..................................................................................................................... 8
1.1. Synopsis ........................................................................................................................................... 8
1.2. Schema .......................................................................................................................................... 11
1.3. Schedule of Activities (SoA) ........................................................................................................... 12
2. INTRODUCTION ................................................................................................................................ 15
2.1. Study Rationale .............................................................................................................................. 15
2.2. Background .................................................................................................................................... 16
2.3. Benefit -Risk Assessment ............................................................................................................... 16
3. OBJECTIVES A ND ENDPO INTS ..................................................................................................... 16
4. STUDY DESIGN ................................................................................................................................ 17
4.1. Overall Design of the Main Study .................................................................................................. 17
4.2. Scientific Rationale for Study Design ............................................................................................. 18
4.2.1. Participant Input Into Design ...................................................................................................... 19
4.2.2. Study-Specific Ethical Design Considera tions ........................................................................... 19
4.3. Justification for Dose ...................................................................................................................... 19
4.4. End of Study Definition ................................................................................................................... 19
5. STUDY POPUL ATION...................................................................................................................... 20
5.1. Inclusion Criteria ............................................................................................................................ 20
5.2. Exclusion Criteria ........................................................................................................................... 22
5.3. Lifestyle Considerations ................................................................................................................. 23
5.4. Screening Failures ......................................................................................................................... 24
5.5. Criteria for Temporary  Delaying (Enrolment/Randomization/Administrati on of Study 
Intervention) (Not Applicable) ........................................................................................................ 24
6. STUDY INTERVENTION ................................................................................................................... 24
6.1. Study Intervention Administered .................................................................................................... 24
6.2. Preparation/Handling/Storage/Accountability ................................................................................ 25
6.3. Measures to Minimize Bias: Randomization and Blinding (Not Applicable) .................................. 26
6.4. Study Interventio n Compliance ...................................................................................................... 26
6.5. Dose Modification ........................................................................................................................... 26
6.6. Continued Access to Study Intervention After the End of the Study (Not Applicable) ................... 26
6.7. Treatment of Overdose .................................................................................................................. 26
6.8. Concomitant Therapy ..................................................................................................................... 26
7. DISCONTINUA TION OF STUDY INTERVENTION A ND PA RTICIPA NT 
DISCONTINUA TION/WITHDRA WAL............................................................................................... 27
7.1. Discontinuation of Study Intervention ............................................................................................ 27
7.1.1. Rechallenge ................................................................................................................................ 27
7.2. Participant Discontinuation/W ithdrawal From the Study ................................................................ 27
7.2.1. Withdrawal From the Use of Research Samples ....................................................................... 28
7.3. Lost to Follow -up............................................................................................................................ 29
7.4. National Disaster/Extra Ordinar y Circum stances .......................................................................... 29
8. STUDY A SSESSMENTS AN D PROCEDURES ............................................................................... 29
8.1. Efficacy  Assessments .................................................................................................................... 30
8.2. Safety Assessments ....................................................................................................................... 30
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 5
Status: Approved ,  Date: 20 April 20218.2.1. Physical Examinations ................................................................................................................ 31
8.2.2. Vital Signs ................................................................................................................................... 31
8.2.3. Electrocardiograms ..................................................................................................................... 31
8.2.4. Clinical Safety Laborator y Assessments .................................................................................... 31
8.3. Adverse Events and Serious Adverse Events ............................................................................... 31
8.3.1. Time Period and Frequency for Collecting Ad verse Event and Serious Adverse Event 
Information .................................................................................................................................. 32
8.3.2. Method of Detecting Adverse Events and Serious Adverse Events .......................................... 32
8.3.3. Follow -up of Adverse Events and Serious Adverse Events ....................................................... 32
8.3.4. Regulatory Reporting Requirements for Ser ious Adverse Events ............................................. 33
8.3.5. Pregnancy ................................................................................................................................... 33
8.3.6. Cardiovascular and Death Events .............................................................................................. 33
8.3.7. Disease -Related Events and Disease -Related Outcomes not Qualifying as Adverse 
Events or Serious Adverse Events ............................................................................................. 33
8.3.8. Adverse Events of Special Interest ............................................................................................. 34
8.4. Pharmacokinetics (Not Applicable) ................................................................................................ 34
8.5. Genetics ......................................................................................................................................... 34
8.6. Biom arkers ..................................................................................................................................... 34
8.7. Immunogenicity Assessments (Not Applicable) ............................................................................. 35
8.8. Health Economics (Not Applicable) ............................................................................................... 35
9. STATISTICA L CONSIDER ATIONS .................................................................................................. 35
9.1. Statistical Hypotheses .................................................................................................................... 35
9.2. Sample Size Determination ........................................................................................................... 35
9.3. Populations for Analy sis Sets ........................................................................................................ 35
9.4. Statistical Analyses ........................................................................................................................ 35
9.4.1. General Considerations .............................................................................................................. 36
9.4.2. Primary Endpoint ........................................................................................................................ 36
9.4.3. Secondary Endpoint ................................................................................................................... 36
9.4.4. Explorator y Endpoint .................................................................................................................. 36
9.4.5. Safety Analyses .......................................................................................................................... 36
9.4.6. Other Analyses ........................................................................................................................... 37
9.5. Interim Analysis (Not Applicable) ................................................................................................... 37
10. SUPPORTING DOCUMENT ATION A ND OPERA TIONA LCONSIDERA TIONS ............................ 38
10.1. Appendix 1: Abbreviations ............................................................................................................. 38
10.2. Appendix 2: Clinical Laboratory Tests ........................................................................................... 40
10.3. Appendix 3: Regulatory, Ethical, and Study Oversight Considerations ......................................... 41
10.3.1. Regulato ry and Ethical Considerations ...................................................................................... 41
10.3.2. Financial Disclosure .................................................................................................................... 44
10.3.3. Informed Consent Process ......................................................................................................... 44
10.3.4. Data Protection ........................................................................................................................... 45
10.3.5. Long- Term Retention of Samples for Additional Future Research ............................................ 46
10.3.6. Committee Structure ................................................................................................................... 46
10.3.7. Publication Policy/Dissemination of Clinical Study Data ............................................................ 46
10.3.8. Data Quality  Assurance .............................................................................................................. 47
10.3.9. Case Report Form Completion ................................................................................................... 48
10.3.10. Sourc e Documents ..................................................................................................................... 48
10.3.11. Monitoring ................................................................................................................................... 49
10.3.12. On-site Audits ............................................................................................................................. 50
10.3.13. Record Retention ........................................................................................................................ 50
10.3.14. Study and Site Start and Closure ............................................................................................... 51
10.4. Appendix 4: Adverse Events, Serious Adverse Events, Product Quality Complaints, and 
Other Safety Reporting: Definitions and Procedures for Recording, Evalua ting, Follow -up, 
and Reporting ................................................................................................................................ .52
10.4.1. Adverse Event Definitions and Classifications ........................................................................... 52
10.4.2. Attribution Definitions .................................................................................................................. 53
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 6
Status: Approved ,  Date: 20 April 202110.4.3. Severity Criteria .......................................................................................................................... 53
10.4.4. Special Reporting Situations ...................................................................................................... 54
10.4.5. Procedures ................................................................................................................................ .54
10.4.6. Product Quality Complaint Handling ........................................................................................... 55
10.4.7. Contacting Sponsor Regarding Safety, Including Product Quality ............................................. 56
10.5. Appendix 5: Contraceptiv e Guidance ............................................................................................ 57
10.6. Appendix 6: Prohibited Concomitant Medications ......................................................................... 60
10.7. Appendix 7: Restricted Concomitant Medications ......................................................................... 61
10.8. Appendix 8: Medications with the Potential for Drug- drug Interactions ......................................... 62
10.9. Appendix 9: Reco mmendations for Management of Drug- related Rash ....................................... 65
10.10. Appendix 10: Phone calls with Participants ................................................................................... 67
10.11. Appendix 11: Instructions for Gentle Skin Care ............................................................................. 68
10.12. Appendix 12: Guidance on Study Conduct during the COVID -19 Pandemic ................................ 69
10.13. Appendix 13: Sub -Study  Protocol .................................................................................................. 72
10.13.1. Protocol Summary ...................................................................................................................... 72
10.13.2. Schema ....................................................................................................................................... 73
10.13.3. Schedule of Activities (SoA) ....................................................................................................... 74
10.13.4. Introduction ................................................................................................................................ .76
10.13.4.1. Study Rationale ....................................................................................................................... 76
10.13.4.2. Benefit -Risk Assessment ......................................................................................................... 77
10.13.5. Objectives and Endpoints ........................................................................................................... 77
10.13.6. SUB-Study Design ...................................................................................................................... 77
10.13.6.1. Overall Design ......................................................................................................................... 77
10.13.6.2. Scientific Rationale for Study Design ...................................................................................... 79
10.13.6.3. Justification for Dose ............................................................................................................... 79
10.13.6.4. End of Study Definition ............................................................................................................ 79
10.13.7. Study Population ......................................................................................................................... 79
10.13.8. Study Intervention ....................................................................................................................... 80
10.13.8.1. Study Intervention Administered .............................................................................................. 80
10.13.8.2. Preparation/Handling/Storage/Accountability .......................................................................... 81
10.13.8.3. Study Intervention Compliance................................................................................................ 81
10.13.8.4. Dose Modification .................................................................................................................... 81
10.13.8.5. Treatment of Overdose ............................................................................................................ 82
10.13.8.6. Concomita nt Therapy .............................................................................................................. 82
10.13.9. Discontinuations of study intervention and Participant discontinuations/withdrawal .................. 82
10.13.9.1. Discontinuation of Study Intervention ...................................................................................... 82
10.13.9.2. Rechallenge ............................................................................................................................. 83
10.13.9.3. Participant Discontinuation/W ithdrawal From the Study ......................................................... 83
10.13.9.4. Lost to Follow -up..................................................................................................................... 83
10.13.9.5. National Disaster/Extra Ordinar y Circum stances .................................................................... 83
10.13.10. Study Assessments and Procedures .......................................................................................... 83
10.13.10.1. Efficacy  Assessments .............................................................................................................. 84
10.13.10.2. Safety Assessments ................................................................................................................ 84
10.13.10.2.1. Electrocardiograms .............................................................................................................. 84
10.13.10.2.2. Adverse Events and Serious Adverse Events ..................................................................... 85
10.13.11. Statistical Considerations ........................................................................................................... 85
10.14. Appendix 14: Sub -Study  Pill Diary ................................................................................................ .86
10.15. Appendix 15: Protocol Amendment History ................................................................................... 88
REFERENCES ............................................................................................................................................ 91
INVESTIGA TOR A GREEME NT................................................................................................................. 93
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 7
Status: Approved ,  Date: 20 April 2021LIST OF IN -TEXT TA BLES A ND FIGURES
TABLES
No entries found.
FIGURES
Figure 1: Schematic Overview of the Main Study .................................................................................... 11
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 8
Status: Approved ,  Date: 20 April 20211. PROTOCOL SUMMARY
1.1. Synopsis
A Multi -center, Open -label, Single -arm Phase 2 Study of the Adjuvant Treatment of Apalutamide and 
Androgen Deprivation Therapy (ADT) in Treatment -naïve Particip ants Who Have Undergone Radical 
Prostatectomy (RP) for Non- metastatic Prostate Cancer and Who Are at High Risk for Metastases
Apalutamide (ERLEADA®), is an orally available, non-steroidal small molecule, which acts as a potent and 
selective antagonist ofandrogen receptor s(ARs).Apalutamide is indicated for the treatment of patients 
with non-metastatic castration -resistant prostate cancer (nmCRPC) and with metastatic castration sensitive 
prostate cancer (mCSPC). Apalutamide is currently being studied for the treatment of prostate cancer at all 
stages.
Given that prostate cancer cells depend on AR for proliferation and survival, astandard treatment for 
patients with recurrent disease is to lower the level of testosterone by surgical castration or with a 
gonadotropin releasing hormone (GnRH) agonist or antagonist , commonly referred to as androgen 
deprivation therapy (ADT).
As a new oral GnRH antagonist (relugolix) has been recently FDA approved, this agent will be part of a 
sub-study detailed in Section 10.13, Appendix 13 .
OBJECTIVES AND ENDPOINTS
Objectives Endpoints
Primary
 To assess if the combination of apalutamide andADT 
in participants with high-risk localized prostate cancer 
improves the BCR -free rate. BCR -free rate at 24 months. BCR is 
defined as a confirmed PSA 
>0.2 ng/mL.
Secondary
 To determine the BCR -free rate at 12 months.  BCR -free rate at 12 months .
 To det ermine the time to serum testosterone recovery . Testosterone recovery rate at 18 and 
24months.
Exploratory
 To evaluate the incidence of rash.  Incidence of rash.
Key: ADT=androgen- deprivation therapy; BCR=biochemical recurrence; PSA=prostate -specific antigen
Hypothesis
The primary hypothesis of this study is that adjuvant treatment with apalutamide and ADT will improve 
the biochemical recurrence (BCR) -free rate at 24 months post radical prostatectomy (RP)in this 
treatment -naïve, non-metastatic prostate cancer population who are at high risk for the development of 
metastases compared to historical data from patients without adjuvant treatment.
OVERALL DESIGN
This is a single -arm, open -label, multi -center study of apalutamide and ADT in approximately 
94participants with high risk localized prostate cancer who are treatment naïve, documented to have no 
evidence of metastatic disease prior to study entry, who are between Day 29 and Day 90post-RP, whose 
prostate -specific antigen (PS A) is ≤0.2ng/mL at study entry and who have recovered from surgery, per the 
clinical judgment of the investigator. There will be one study intervention group receiving apalutamide for 
12 cycles (a cycle is defined as 28 days) ; the participants will also r eceive an ADT of investigator’s choice
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 9
Status: Approved ,  Date: 20 April 2021(3-month depot preferred) for 12 months. Treatment with apalutamide and ADT will start following 
screening and completion of RPand no later than postoperative Day 90.Participants will receive 12cycles 
of therapy. During treatment, participants should continuously be re-evaluated for emerging and worsening  
cardiovascular risk factors per current standards for patients under androgen deprivation. Approximately 
30 days post-treatment, a safety follow -up examination will be completed (end of treatment visit) .There 
will be a follow -up period during which serum PSA and testosterone levels will be measured and clinical 
status monitored every 6 months after the completion of treatment until the end of the study (EOS). The 
EOS is defined as the date of last participant’s enrol lment +24 months or discontinuation of all study 
participants from the study, whichever occurs first. Study enrollment is defined as the day when the 
participant receives the first dose of apalutamide a fter having met all prescreening criteria.
A Steering Committee will be commissioned for this study.
NUMBER OF PARTICIPANTS
This study will be conducted in approximately 30urology practices in the United States and enroll 
approximately 94 participants. The sub-study consisting of 12 participants will be in addition to the 94 main 
ApaRP protocol and statistical analyses will be performed separately. Upon completion of the sub-study, 
participants will be transitioned into the main study beginning at Cycle 2 Day 1.
INTERVENTION GROUPS AND DUR ATION
Participants will be instructed to take their assigned dose of the study intervention (apalutamide) orally
once daily for 12cycles per apalutamide United States Package Insert (ERLEADA®USPI ).A treatment 
cycle is defined as 28 days. There will be one study intervention group receiving apalutamide along with 
ADT of investigator’s choice (3-month depot preferr ed).Androgen deprivation therapy will be given for 
12months.
EFFICACY EVALUATIONS
Efficacy assessments include serum PSA and testosterone and will be assessed prior to first dose of study  
intervention and throughout the study per the Schedule of Activities (SoA). A PSA level >0.2 ng/mL, 
(confirmed within 3- 4 weeks), will be considered an indicator of BCR .
BIOMARKER EVALUATIONS
Biomarker samples may be collected as outlined in the SoA. Biomarker analysi s is planned to 
retrospectively evaluate risk scores and other genomic markers and correlate with participant s’ response to 
treatment and explore homologous recombinant deficiency (HRD) and efficacy of apalutamide in this 
subpopulation. To address these ob jectives, tumor tissue will be collected and sent to sponsor’s laboratory 
partner along with a copy of the full histopathology report of the specimen . Also, whole blood and plasma
samples may be collected at baseline, 12months or end of treatment, and at 24months or progression 
(whichever comes first) .
SAFETY EVALUATIONS
Participants will be monitored for safety from the beginning of the treatment and at each study visit. Events 
related to and associated with the recovery from the pre- planned RPwill not be collected.
Focused physical examinations including skin assessment will be completed prior to treatment, and at 2, 3, 
4, 7, 10, 13, and 14 months . A 12-lead electrocardiogram (ECG) will be conducted prior to treatment to 
assess for QT prolongation, if not available from pre-operative evaluation. Blood samples specific to the 
study will be collected only for PSA, testosterone levels ,and biomarkers.
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 10
Status: Approved ,  Date: 20 April 2021STATISTICAL METHODS
The primary hypothesis of this study is that adjuvant treatment with apalutamide andADT will improve 
the BCR -free rate at 24 m onths in the treatment -naïve , non- metastatic prostate cancer population who are 
at high risk for the development of metastases compared to historical data from patients without adjuvant 
treatment (76%) .
It is estima ted that approximately 94 participants treated for 12months and followed for an additional 
12months would be required to provide at least 80% power in detecting a 10% absolute increase in 
BCR -free rate at 24 months from 76% to 86% at a 1-tailed significa nce level of 0.05. Sample size was 
calculated using PASS 15 (Power Analysis and Sample Size Software [2017]). Time to BCR 
(ie,PSA >0.2 ng/mL) will be analyzed using Kaplan- Meier method. The secondary endpoint of 
testosterone recovery will be analyzed similarly to the primary endpoint. Incidence of rash will be 
summarized descriptively .
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 11
Status: Approved ,  Date: 20 April 20211.2. Schema
Figure 1: Schematic Overview of the Main Study
*See Section 9.4.5 , Safety Analyses for details .
Key: ADT=androgen deprivation therapy; EOS=end ofstudy; N=number of participants; post -op=postoperative; 
PSA=prostate -specific antigen; RP=radical prostatectomy .
Definition of High -Risk population:
•PSA ≥20 ng/mL or 
•Gleason Score ≥9 in any core on biopsy or 
•Gleason Score ≥8 (4+4 or 5+3) in >80% of 2 cores on biopsy or 
•Gleason Score = 8 (4+4 or 5+3) in 1 core as long 5 or more other cores with minimum Gleason Score of 4+3 on biopsy
The determination of high risk may be based on pathology report of biopsy or equivalent criteria from radical 
[STUDY_ID_REMOVED]
[STUDY_ID_REMOVED]
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 14
Status: Approved ,  Date: 20 April 2021fA PSA level >0.2 ng/mL will be an indicator of BCR and w ill be confirmed within 3 to 4 weeks regardless of study visit and timing. Depending on timing, this may 
be captured as an unscheduled visit.
gFocused examinations are generally limited to the body systems or regions based on participant’s self -assessment and AE reporting. Any new comp laints, symptoms
reported by participants or adverse events noted by providers should guide the need and extent of physical examination.
hECG assessment at screening if not available from p reoperative information.
iCollected at baseline, 12 months or end of treatment, and at 24 months or progression (whichever comes first) .
jTissue sample to be collected and sent to sponsor’s laboratory partner along with a copy of the full histopathology report of the specimen .Biopsy tissue is preferred.
See Section 8.6for further details.
kCollection of concomitant therap iesdoes not begin until time of first dose of apalutamide .
LCollection of AEsdoes not begin until time of first dose of apalutamide .
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 15
Status: Approved ,  Date: 20 April 20212. INTRODUCTION
Prostate cancer is the second most frequentl y diagnosed cancer and the sixth leading cause of 
cancer death in males worldwide.12Treatment aimed at eradicating the primary  tumor, typically 
with surgery  or radiation, is unsuccessful in 30% of men, who develop recurrent disease that 
usually  manifests first as a rise in prostate -specific antigen (PSA)followed by spread to distant 
sites.27Given that prostate cancer cells depend on androgen sfor proliferation and survival, a
standard treatment for patients with recurrent disease isto lower the level of testosterone by 
surgical castration or with a gonadotropin releasing hormone (GnRH ) agonist or antagonist , 
commonly  referred to as androgen deprivation therap y (ADT ).
Apalutamide (ERL EADA®) is an orally available, non-steroidal small molecule, which acts as a 
potent and selective antagonist of androgen receptors (ARs). To date, apalutamide has been 
approved for the treatment of patients with non-metastatic castration -resistant prostate cancer 
(nmCRPC )and with metastatic castration -sensitive prostate cancer (mCSPC ).Apalutamide is 
currentl y being studied for the treatment of prostate cancer at all stages.
For the most comprehensive nonclinical and clinical information regarding apalutamide , refer to 
the latest version of the Invest igator's Brochure (IB)11and US Package Insert (ERL EADA®USPI ) 
forapalutamide .
Common terms used throughout the protocol are noted. The term “stud y intervention” throughout 
the protocol, refers to apalutamide + ADT .The term "sponsor" refers to the entities listed in the 
Contact Information page(s), which will be provided as a separate document. The term 
"participant" throughout the protocol refers to the common term "subject".
2.1. Study Rationale
Men with high risk localized prostate cancer frequently  undergo radical prostatectomy (RP)17with 
curative intent. While asignificant proportion ofpatients with clinicall ylocalized prostate cancer
are cured by definitive local therapy ,22patients with high -risk features, including
Gleason score 8to10,positive lymph node involvement, high initial prostate -specific antigen, 
seminal vesicle invasion and extra prostatic extension have a 40%to 75% chance ofdisease
recurrence in10years.5,16,26In the National Comprehensive Cancer Network (NCCN )
guidelines,17there is a Category 1 adjuvant radiation therap y option but no standard adjuvant 
systemic therap y option for men with most of these clinical features. There is evidence supporting 
ADT in the adjuvant setting but only for men with node positive prostate cancer.15There is also 
evidence supporting postoperative adjuvant radiation therap y28in patients with high and very high
risk disease but it is infrequently  and inconsistently  applied in these situations. Apalutamide and 
ADT have demonstrated the ability  to significantly  prolong metastasis -free survival (MFS ), 
radiographic progression free survival ( rPFS ), and overall survival in2large randomized, double 
blind, placebo controlled registrational trials.4,25This study  willinvestigate whether treatment with 
apalutamide and ADT for 12mont hs can improve thechance of maintaining participants free of 
biochemical recurrence (BCR )with a serum PSA ≤0.2 ng/mL 24months after RP. In other solid 
tumors, robust adjuvant strategies are available that guide treatment decision- making after surgery . 
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 16
Status: Approved ,  Date: 20 April 2021This guidance is lacking in prostate cancer and this study  can help to inform the development of 
such a strategy  for this unmet need.
2.2. Background
High -risk prostate cancer accounts for approximately  15% of newl y diagnosed prostate cancers.3
For patients with high-risk, locally  advanced prostate cancer, prostatectomy  alone may be 
inadequate. Cure rates from prostatectomy  are less than 25%.2,15,23High -risk patients experience 
the highest recurrence after prostatectomy , with a disease progression rate of approximately  50%.13
Patients with recurring disease after local therapy  require salvage radio therapy , which is associated 
with morbidity  that hasdetrimental impact on quality  of life. In a retrospective analysis of 379 
men who developed a BCR after RP, it was found that patients with a Gleason score of 8 to 10 
were more likel y to die from prostate cancer than patients with a Gleason score of 7 or less.7
Several deﬁnitions of high-risk prostate cancer are used in the urological literature. Patients with 
high-risk localized or locally  advanced prostate cancer include those with Gleason scores ≥8, 
clinical stage ≥cT2c (disease in both or extension outside of the lobes), high baseline 
PSA ≥20ng/mL , or involvement of regional nodes. For the current study , high risk is defined by 
Gleason score orPSA.
For adjuvant use of ADT, prospective randomize d studies have shown that earl y use of long-term
ADT extends survival, compared with treatment that is delay ed until disease progression.2,5,6,9,21
In a randomized study  in 100 patients to determine whether immediate ADT extends survival in 
patients with node -positive prostate cancer who have undergone RPand pelvic lymphadenectom y 
compared with those who received ADT onl y at disease progression, it was shown that earl y ADT  
benefits patients as compared to deferred treatment.15
2.3. Benefit -Risk Assessment
More detailed information about the known and expected benefits and risks of apalutamide may 
be found in the IBand ERL EADA USPI .
As noted in Section 2.1, there is evidence that adjuvant therap y ma y provide benefit.
3. OBJECTIVE S ANDENDPOINTS
Objectives Endpoints
Primary
 Toassess if the com bination of apalutamide andADT 
in participants with high-risk localized prostate cancer 
improves the BCR -free rate. BCR -free rate at 24 months. BCR is 
defined as a confirmed PSA 
>0.2 ng/mL.
Secondary
 To determine the BCR -free rate at 12 months.  BCR -free rate at 12 months .
 To determine time to serum testosterone recovery .  Testosterone recovery rate at 18 and 
24months.
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 17
Status: Approved ,  Date: 20 April 2021Objectives Endpoints
Exploratory
 To evaluate the incidence of rash.  Incidence of rash.
Key: ADT=androgen-depriv ation therapy; BCR= biochemical recurrence ; PSA=prostate -specific antigen
Refer to Section 8, Study Assessments and Procedures for evaluations related to endpoints.
HYP OTHESIS
The primary  hypothesis of this study  is that adjuvant treatment with apalutamide and ADT will 
improve the BCR -free rate at 24 months post-RP in this treatment -naïve ,non-metastatic prostate 
cancer population who are at high risk for the development of metastases compared to historical 
data from patients without adjuvant treatment.14
4. STUDY DESIGN
4.1. Over allDesign of the Main Study
This is a single -arm, open -label , multi- center study  of apalutamide andADT in approximately
94participants with high risk localized prostate cancer who are treatment naïve, documented to 
have no evidence of metastatic disease prior to study  entry, who are between Day 29and Day 90
post-RP, whose PSA is ≤0.2 ng/mL  at study  entry and who have recovered from surgery , per the 
clinical judgment of the investigator .
This study  will be conducted in approximately  30 urology  practices in the USand enroll 
approximately  94 partici pants. There will be one study  intervention group receiving apalutamide 
for 12 cycles; the participants will also receive anADT of investigator’s choice (3-month depot 
preferred ) for 12months. Treatment with apalutamide and ADT will start following scree ning and 
completion of RPand no later than postoperative Day90. Approximately  30 day s post -treatment, 
a safet y follow -up exam ination will be completed (end of treatment visit) .There will be a 
follow -upperiod during which serum PSA and testosterone levels will be measured and clinical 
status monitored every  6 m onths after the completion of treatment until the end of study  (EOS ). 
The EOS is defined as the date of last participant’s enrollment +24 months or discontinuation of 
all study  participants from the study , whichever occurs first. Study  enrollment is defined as the 
day when the participant receives the first dose of apalutamide after having met all prescreening 
criteria.
During treatment, participants should continuously  be re-evaluated for emerging and worsening 
cardiovascular risk factors per current standards for patients under androgen deprivation. 
Management of risk factors, including but not limited to hypertension (inclusive of blood pressure 
fluctuations and interim hypotension), overweight/obesity , and hyperlipidemia is required for all 
participants based on recent guidelines.
The timing and frequencies of study assessments are presented in the SoA (Section 1.3). Efficac y 
assessments include serum PSA and testosterone and will be assessed after the start of apalutamide 
treatment. A PSA level >0.2 ng/mL (confirmed within 3-4weeks) is considered an indicator of 
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 18
Status: Approved ,  Date: 20 April 2021BCR .Safet y assessments from the time of enrollment and during treatment and end of treatment 
visit will include focused physical examinations, monitoring of adverse events (AEs). A 12-lead 
electrocardiogram (ECG )will be conducted at screening to examine QT prolongation, if not 
available from preoperative evaluation. Safet y evaluations will be conducted based on AE 
reporting. Blood and plasma sample sfor biomarker analy sis as well as tumor tissue will be 
collected per the Schedule of Activities (SoA).
A Steering Committee will be commissioned for this study . Refer toCommittees Structure in 
Section 10.3, Appendix 3, Regulatory , Ethical, and Study  Oversight Considerations for details.
A diagram of the stud y design is provided in Section 1.2, Schema .
4.2. Scientific Rationale for Study  Design
The single -arm, open -label design is appropriate for a Phase 2 study  to evaluate the clinical benefit 
of adjuvant apalutamide with ADT for patients with high- risk localized prostate cancer following 
RP.The occurrence of rash with apalutamide and subsequent specific management could make 
blinding impractical. The participants have previously  selected to undergo RP as opposed to any 
other option and their participation in this study  with adjuvant treatment could provide added 
benefit to them.
Following the work conducted by  the ICECaP investigator s29whose results were obtained mostly  
in patients who had undergone radiation therap y with curative intent, Martini et al14described the 
biochemical and clinical recurrence patterns in a cohort of 3,507 patients with high risk localized 
prostate cancer who had undergone RPand extended pelvic lymph node dissections. These 
investigators noted negligible serum PSA (≤0.2 ng/mL) rates of 84% and 76% at 12 and 
24months, respectively after surgery, in the absence of an y adjuvant treatment. These findings on 
biochemical recurrence form the basis for the statistical assumptions and rationale for clinical 
endpoints in this adjuvant study (see Section 9.2).
Biomarker Collection
It is recognized that genetic variation can be an important contributory  factor to interindividual 
differences in intervention and response and can also serve as a marker for disease susceptibility  
and prognosis.
Biomarker samples may be collected to evaluate progression or help to explain interindividual 
variability  in clinical outcomes and may help to identify  population subgroups that respond 
differentl y to thisintervention . The goal of the biomarker analyses is to evaluate localized high-risk
prostate cancer population and aid in evaluating the intervention -clinical response relationship of 
apalutamide with ADT .
Biomark er samples may be used to help address emerging issues and to enable the development 
of safer, more effective, and ultimately  individualized therapies.
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 19
Status: Approved ,  Date: 20 April 20214.2.1. Participant Input Into Design
As part of the Patient Voice Project, members of the Prostate Cancer Patient Engagement Research 
Council who are all patients/survivors of prostate cancer favorabl y reviewed the study design and 
visit schedule.
The consensus was that the open -label design, without placebo, of this study  is preferable to 
randomized double -blind studies for patients. Additionally, the visit schedule and duration of time 
on study  was not considered “burdensome” .Longer follow -up was suggested and follow -upevery 
6months until the end of the study  was added with subsequent follow -up to be covered by
treatment per standard of care.
4.2.2. Study -Specific Ethical Design Considerations
Potential participants will be fully informed of the risks and requirements of the study and, during 
the study , participants will be given any new information that may affect their decision to continue 
participation. They  will be told that their consent to participate in the study is voluntary  and may 
be withdrawn at any time with no reason given and without penalt y or loss of benefits to which 
they would otherwise be entitled. Only participants who are fully  able to understand the risks, 
benefits, and potential AEs of the study, and provide their consent voluntarily  will be enrolled.
While participants have selected RPindependent from this study , the primary  ethical concern is 
that adjuvant therap y with apalutamide following RPis not currently  standard of care. The cure 
rate for patients with high-risk localized prostate cancer is approximately 25%. Apalutamide has 
been proved to significantly  delay  metastases and improve overall survival, and has a manageable 
safet y profile.25Participants may discontinue from the study  if there are signs of disease 
progression and then be eligible for other forms of treatment including radiation.
An additional ethical concern is germline and other genetic testing which may warrant counse lling. 
This information and potential interventions may affect not only the participant, but his family . 
Genetic counselling will be made available through the genetic testing facility .
The total blood volume to be collected is considered to be an acceptable amount of blood to be 
collected over this time period from the population in this study  based upon thestandard of the
American Red Cross.1
4.3. Justification for Dose
The dose of 240 mg (4 × 60 mg tablets ) is the approved dose per ERL EADA USPI .
4.4. End of Stud y Definition
End of Study Definition
The EOS is defined as the date of last participant’s enrol lment +24 months or discontinuation of 
all study  participants from the study , whichever occurs first. The final data from the study  site will 
be sent to the sponsor (or designee) after completion of the final participant visit at that study site, 
in the time frame specified in the Clinical Trial Agreement.
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 20
Status: Approved ,  Date: 20 April 2021Study Completion Definition
Participant swill be considered to have completed the study  if they have completed EOS 
assessments .
Participants who prematurely  discontinue study  intervention for any reason before study  
completion will not be considered to have completed the study .If a participant misses a dose for 
>28days, consult the sponsor regarding continuation in the study .
5. STUDY POPULA TION
The study  population will consist of participants that are treatment -naïve, who have undergone RP 
for non-metastatic prostate cancer ,and who are at high risk for metastases, as defined by Gleason 
score orPSA.
Screen ing for eligible participants will be performed within 90days before administration of the 
study  intervention .Refer to Section 5.4,Screen Failures for conditions under which the repeat of 
any screening procedures are allowed .
The inclusion and exclusion criteria for enrolling participants in this stud y are described below . If 
there is a question about the secriteria, the investigator must consult with the appropriate sponsor 
representative and resolve any issues before enrolling a participant in the study . Waivers are not 
allowed. 
For a discussion of the statistical considerations of participant selection, refer to Section 9.2, 
Sample Size Determination .
5.1. Inclusion Criteria
Each potential participant must satisfy  all of the following criteria to be enrolled in the study :
1. m ale>18 years of age
2. m ust be willing and able to sign an informed consent form and be able to fully  comply 
with all of the required procedures, restrictions, and prohibitions specified in this protocol
3. C riterion modified per Amendment 2
3.1 The participant should be
a.a candidate for RPor status post -RP
b.eligible to receive stud y intervention between Day 29 and Day 90 post -RP
c.post-RP PSA of <0.2 ng/mL  
d. h asnot received other treatment for prostate cancer
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 21
Status: Approved ,  Date: 20 April 20214. C riterion modified per Amendment 2
4.1 have recovered from RPprocedure and have had no worsening in cardiac risk in 
the peri -operative period per the clinical judgment of the investigator
5. Criteri on modified per Amendment 1
5.1. C riterion modified per Amendment 2
5.2 h istologically  confirmed adenocarcinoma of the prostate and categorized as high 
risk for recurrent prostate cancer. High risk can be defined based on PSA alone or biopsy 
or RP specimen asfollows :
PSA ≥20ng/mL
or
Gleason Score ≥9 in an y core on biops y
or
Gleason Score ≥8 (4+4 or 5+3) in > 80% of 2 cores on biopsy
or
Gleason Score = 8 (4+4 or 5+3) in 1 core as long 5 or more other cores with 
minimum Gleason Score of 4+3 on biopsy
The determination of high risk may be based onpathology  report ofbiopsy  or equivalent 
criteria from radical prostatectomy .
6. adequate organ function (hepatic, renal, hematologic and cerebral) determined at the 
discretion of the treating phy sician
7. Easte rn Cooperative oncology  Group ( ECOG) Performance Status S core of 0 or 1
8. a ble to take apalutamide per the ERLEADA USPI and able to receive ADT for up to 1 
year
9. must be willing to wear a condom when engaging in any  activity  that allows for passage 
of ejaculate to another person. M ale participants should also be advised of the benefit for 
a female partner to use a highl y effective method of contraception as condom may  break 
or leak
10. must be willing toagree not to donate sperm for the purpose of reproduction during the 
study  and for a minimum 90 daysafter receiving the last dose of stud y intervention
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 22
Status: Approved ,  Date: 20 April 20215.2. Exclusion Criteria
Any potential participant who meets any of the following criteria will be excluded from 
participating in the stud y:
1. Criteri on modified per Amendment 1
1.1. history  or presence of soft tissue /bone metastasis or metastasis indistant lymph 
nodes ( pelvic lymph nodes below the iliac bifurcation that are <2 cm in diameter [short 
axis] either radiographically  or pathologicall y are allowed.)
2. h istory  of bilateral orchiectomy
3. taking anydisallowed therapies or chronic need forprohibited medications (per 
ERL EADA USPI) as noted in Section 6.8, Concomitant Therap y before the planned 
first dose of study  intervention
4. received an investigational intervention ≤4 weeks before the planned first dose of stud y 
intervention
5. history  of seizure or any condition that in the opinion of the investigator may predispose 
to seizure or treatment with drugs known to lower the seizure threshold within 4 weeks 
prior to starting treatment with apalutamide
6. allergy  or hypersensitivity  to apalutamide, or excipients, unable or unwilling to take 
ADT
7. history  or presence of psoriasis, neurodermatitis, acneiform rashes or any 
dermatological condition that in the opinion of the investigator may predispose to 
confounding wit h the evaluation and management of study  intervention related rash
8. Criterion modified per Amendment 2
8.1 m alignancies (ie, progressing or requiring treatment or treatment change in the 
last 24 months) other than prostate cancer. The only allowed exceptions are: non-muscle 
invasive bladder cancer; skin cancer (non-melanoma or melanoma) treated within the 
last 24 months that is considered completel y cured . Malignancies considered cured for 
more than 24 months are allowed
9. Criterion modified per Amendment 1
9.1 Criteria modified per Amendment 2
9.2 any of the following within 12 months prior to baseline :severe or unstable 
angina, myocardial infarction, symptomatic congestive heart failure, uncontrolled 
hypertension, long QT, arterial or venous thromboembolic events (eg,pulmonary 
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 23
Status: Approved ,  Date: 20 April 2021embolism, cerebrovascular accident including transient ischemic attacks), or clinically  
significant ventricular arrhy thmias
10. plans to father a child while enrolled in this stud y or within 12 weeks after the last dose 
of study  intervention
11. any condition for which, in the opinion of the investigator, participation would not be 
in the best interest of the participant (eg, compromise the well-being) or that could 
prevent, limit, or confound the protocol -specified asse ssments
NOTE : Investigators should ensure that all study  enrollment criteria have been met at screening. 
If a participant 's clinical status changes (including any available laboratory  results or receipt of 
additional medical records ) after screening but b efore the first dose of study  intervention is given 
such that theparticipant nolonger meets all eligibility  criteri a, then the participant should be 
excluded from participation in the study . The required source documentation to support meeting 
the enrollment criteria are noted in Section 10.3, Appendix 3, Regulatory, Ethical, and Study 
Oversight Considerations.
5.3. Lifestyle Considerations
Potential participants must be willing and able to adhere to the following lifest ylerestrictions 
during the course of the study  to be eligible for participation:
1. Refer to Section 6.8,Concomitant Therap yfor details regarding prohibited and 
restricted therap y during the study , including chronic alcohol use, 
cytochrome P450 (CYP )3A4 interaction, and drugs known to lower the seizure 
threshold or cause seizures.
2. Agree to follow all requirements that must be met during the study  as noted in the 
Inclusion and Exclusion Criteria (eg, contraceptive requirements ).
3. Orchiectom y is prohibited during the entire stud y.
4. A condom is required for all sexual activity  during the study  and for 3 months after 
completion of apalutamide. There is no sperm donation permitted during the study  and 
within 3 months after completion of study  treatment. See Section 10.5, Appendix 5, 
Contraceptive Guidance for further details.
5. If the study  participant is engaged in sexual activity  with a female of childbearing 
potential, 2 forms of contraception, including condom use as described above, are 
required. These include:
Oral, injected or implanted methods of contraception including an intrauterine 
device (I UD) or intrauterine sy stem (IUS)
Barrier methods with spermicide
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 24
Status: Approved ,  Date: 20 April 2021Vasectom y
5.4. Screen ingFailures
Participant Identification, Enrollment, and Screening Logs
The investigator agrees to complete a participant identification and enrollment log to permit easy  
identification of each participant during and after the study . This document will be reviewed by 
the sponsor study -site contact for completeness.
The participant identification and enrollment log will be treated as confidential and will be filed 
by the investigator in the study  file. To ensure participant confidentiality , no copy will be made. 
All reports and communications relating to the study  will identify  participants by participant 
identification and age at initial informed consent . In cases where the participant is not enrolled into 
the study , the date seen and age at initial informed consent will be used.
Participants who do not meet the criteria for participation in this study  (screen failure) will not be 
rescreened.
5.5. Criteria for Temporary Delay ing (Enr olment/Randomization/A dministration 
of Study Intervention) (Not Applicable)
6. STUDY INTERVENTION
6.1. Study Intervention Administered
The study  intervention apalutamide, 240mg(four 60mg tablets, slightly yellowish togreyish
green oblong film-coated tablets, debossed with “AR 60” on one side), will be provided as tablets 
for oral administration. The window for initiation of study  intervention must occur between Day 
29 and Day 90 post-RP.Participants will be instructed to take their assigned dose of the study 
intervention orally once daily for 12 cycles per ERL EADA USPI .A treatment cy cle is defined as 
28 days.Apalutamide canbe taken with or without food.If a participant experiences a ≥Grade 3 
toxicity  or an intolerable side effect, hold dosing until sy mptom s improve to ≤Grade 1 or original 
grade, then resume at the same dose or a reduced dose (180 mg or 120 mg), if warranted. If a 
participant remains off apalutamide for ≥4weeks, the participant may be withdrawn from the 
study , after discussing with the spon sor. Participants experiencing treatment related seizure of an y 
grade will have apalutamide permanentl y discontinued.
Description of Interventions
Study  intervention administration must be captured in the source documents and the electronic 
case report form (eCRF ). Study -site personnel will instruct participants on how to store study 
intervention for at -home use as indicated for this protocol.
Apalutamide will be manufactured and provided under the responsibility  of the sponsor. Refer to 
the IB for a list of excipients and the ERLEADA USPI .
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 25
Status: Approved ,  Date: 20 April 2021Investigator’s choice of a Food and Drug Administration (FDA )-approved and commercially 
available ADT, not provided by the sponsor, will be administered perthe USPI  for 12months in 
total duration, during the treatment phase. Three -month depot is the preferred administration. For 
further information on ADT refer to the USPI.
For a definition of study  intervention overdose, refer to Section 6.7, Treatment of Overdose.
6.2. Preparation/Handling/Storage/A ccountability
Preparation/Handling/Storage
Apalutamide must be stored at controlled temperatures ranging from 15 °C to 30°C.
Refer to the ERL EADA USPI for additional guidance on apalutamide and ADT preparation, 
handling, and storage.
Accountability
The investigator is responsible for ensuring that all study  intervention received at the site is 
inventoried and accounted for throughout the study. The study  intervention administered to the 
participant must be documented on the intervention accountability  form. All study  intervention
will be stored and disposed of according to the sponsor's instructions. Study -site personnel must 
not combine cont ents of the study  intervention containers.
Study  intervention must be handled in strict accordance with the protocol and the container label, 
and must be stored at the study  site in a limited -access area or in a locked cabinet under appropriate 
environmental conditions. Unused study  intervention, and study  intervention returned by the 
participant, must be available for verification by the sponsor's study  site monitor during on-site 
monitoring visits. The return to the sponsor of unused study  intervention, or used returned study  
intervention for destruction, will be documented on the intervention return form. When the study 
site is an authorized destruction unit and study  intervention supplies are destroy ed on-site, this 
must also be documented on the intervention return form.
Study  intervention should be dispensed under the supervision of the investigator or a qualified 
member of the study -site personnel, or by  a hospital/clinic pharmacist. Study  intervention will be 
supplied only to participants participating in the study . Returned study  intervention must not be 
dispensed again, even to the same participant. Study  intervention may not be relabeled or 
reassigned for use by other participants. The investigator agrees neither to dispense the study  
intervention from, nor store it at, any  site other than the study  sites agreed upon with the sponsor . 
Further guidance and information for the final disposition of unused study  interventions are 
provided in the Study  Site Investigational Product and Procedure s Manual.
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 26
Status: Approved ,  Date: 20 April 20216.3. Measures to Minimize Bias: Randomization and Blinding (Not Applicable)
6.4. Study Intervention Compliance
Study -site personnel will maintain a log of all study  intervention dispensed. Study  intervention 
supplies for each participant will be inventorie d and accounted for.
6.5. Dose Modification
Any dose adjustment should be overseen b y medically qualified study -site personnel (principal or 
subinvestigator unless an immediate safet y risk appears to be present).
In case a dose modification is necessary , the study intervention will be administered per 
Section 10.9, Appendix 9, Recommendations for Management of Drug-related Rash.
6.6. Continued A ccess to Study In tervention After the End of the Study  (Not 
Applicable)
6.7. Treatment of Overdose
For this study , any  dose of apalutamide greater than 240 mg within a 24 -hour time period will be 
considered an overdose. The sponsor does not recommend specific intervention foran overdose. 
There is no specific antidote and treatment should consist of general supportive measures.
In the event of an overdose, the investigator or treating ph ysician should:
Contact the Medical Monitor immediately .
Closely  monitor the participant for adverse event ( AE)/serious adverse event ( SAE ).
Document the quantit y of the excess dose as well as the duration of the overdosing in the 
eCRF.
Decisions regarding dose interruptions or modifications will be made by the investigator in 
consultation with the Medical Monitor based on the clinical evaluation of the participant.
6.8. Concomitant Therapy
Concomitant therapies must be recorded throughout the study  from the time of first dose of study  
intervention to the last study  visit. Concomitant therapies should also be recorded beyond 30days 
after last study  visit only in conjunction with new or worsening AEs and SAEs that meet the criteria 
outlined in Section 8.3.1 , Time Period and Frequency for Collecting Adverse Event and Serious 
Adverse Event Information .
All therapies (prescription or over-the-counter medications, including vaccines, vitamins, herbal 
supplements; non-pharmacologic therapies such as electrical stimulation, acupuncture, special 
diets, exercise regimens , or other specific categories of interest ) different from the study 
intervention must be recorded in the eCRF . Recorded information will include a des cription of the 
type of therapy , duration of use, dosing regimen, route of administration, and indication .
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 27
Status: Approved ,  Date: 20 April 2021Modification of an effective preexisting therap y should not be made for the explicit purpose of 
entering a participant into the study .
Prohibited concomitant therap ies,outlined in Section 10.6 Appendi x 6, include treatment with any 
AR blocker or CYP17 inhibitor for the treatment of prostate cancer. Sipuleucel -T,pembrolizumab, 
radium -223, strontium -89, samarium -153, saw palmetto and any agent under investigation and not 
currentl y approved by the FDA for any indication are also prohibited. Concomitant therapy 
restrictions are outlined in Section 10.7, Appendix 7, Restricted Concomitant Medications .
The sponsor must be notified in advance (or as soon as possible thereafter) of any instances in 
which prohibited therapies are administered.
7. DISCONTINUA TION OF STUDY INTERVENTION A ND PA RTICIPA NT 
DISCONTINUA TION/ WITHDRA WAL
7.1. Discontinuation of Study Intervention
A participant's stud y intervention must be discontinued if:
The participant withdraws consent to receive stud y intervention
The investigator believes that for safety  reasons or tolerability  reasons (eg,AE) it is in the 
best interest of the participant to discontinue study intervention
Noncompliance with study  intervention administration
Participants experiencing treatment -related seizure of any grade will have apalutamide 
permanentl y discontinued
If a participant discontinues study  intervention for any  reason before the end of the study ,then the
last scheduled study assessments should be obtained and scheduled assessments off study 
intervention should be continued. If a participant misses dosesfor >28 days, consult the sponsor 
regarding continuation in the study . If a participant discontinues study  intervention due to disease 
progression, the subsequent treatment including radiation will be captured in the eCRF, if known . 
Additional participants will not be entered to ensure the protocol -specified number of participants 
complete the study .
7.1.1. Rechallenge
If a participant experiences a ≥Grade 3 toxicity  or anintolerable side effect, hold dosing until 
symptoms improve to ≤Grade 1 or original grade, then resume at the same dose or a reduced dose, 
if warranted per Section 10.9, Appendix 9,Recommendations for Management of Drug Related
Rash .
7.2. Participant Discontinuation/ Withdrawal From the Study
A participant will be withdrawn from the study  for any  of the following reasons:
Lost to follow -up
Withdrawal of consent
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 28
Status: Approved ,  Date: 20 April 2021Investigator’s discretion
Seizure
Death
When a participant withdraws before study completion , the reason for withdrawal is to be 
documented in the eCRF and in the source document. If the reason for withdrawal from the stud y 
is withdrawal o fconsent, then no additional assessments are allowed.
Withdrawal of Consent
A participant declining to return for scheduled visits does not necessarily constitute withdrawal of 
consent. Alternate follow -up mechanisms that the participant agreed to when sign ing the consent 
form apply (eg, consult with family  members, contacting the participant’s other physicians, 
medical records, database searches, use of locator agencies at study  completion) as local 
regulations permit.
Prior to a participant withdrawing consent for follow -up, the investigator should offer the 
participant an opportunity  for one of the alternative reduced follow -up mechanisms described 
below . Withdrawal of consent should be an infrequent occurrence in clinical studies, therefore, 
prior to the start of the study ,the sponsor and the investigator should discuss and reach a clear 
understanding of what constitutes withdrawal of consent in the context of the available reduced 
follow -up mechanisms listed.
7.2.1. Withdrawal From the Use of Research Samples
Aparticipant who withdraws from the study  will have the following options regarding the research 
sample s:
The collected sample swill be retained and used in accordance with the participant's original 
informed consent .
The participant may withdraw consent for research sample s, in which case the sample swill 
be destro yed, and no further testing will take place. To initiate the sample destruction process, 
the investigator must notify  the sponsor study  site contact of withdrawal of consent for the 
research samp les and to request sample destruction. The sponsor study  site contact will, in 
turn, contact the biomarker representative to execute sample destruction. If requested, the 
investigator will receive written confirmation from the sponsor that the sample has been 
destroy ed.
Withdrawal From the Use of Samples in Future Research
The participant may withdraw consent for use of samples for research (refer to Long -term 
Retention of Samples for Additional Future Research in Section 10.3, Appendix 3, Regulatory , 
Ethical, and Study  Oversight Considerations ). In such a case, samples will be destroyed after they 
are no longer needed for the clinical study . Details of the sample retention for research are 
presented in the main informed consent form ( ICF).
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 29
Status: Approved ,  Date: 20 April 20217.3. Lost to Follow -up
To reduce the chances of a participan t being deemed lost to follow -up,prior tostudy  entry, 
attempts should be made to obtain contact information from each participant, eg, home, work, and 
mobile telephone numbers and email addresses for both the participant as well as appropriate 
family  mem bers.
Participant swill be considered lost to follow -up if they repeatedl y fail to return for scheduled visits 
and is unable to be contacted by the study  site. A participant cannot be deemed lost to follow -up 
until all reasonable efforts made by  the study -site personnel to contact the participant are deemed 
futile. The following actions must be taken if a participant fails to return to the study  site for a 
required stud y visit:
The study -site personnel must attempt to contact the participant to reschedule t he missed visit 
as soon as possible, to counsel the participant on the importance of maintaining the assigned 
visit schedule, to ascertain whether the participant wishes to or should continue in the study .
Before a participant is deemed lost to follow up, the investigator or designee must make every  
reasonable effort to regain contact with the participant (where possible, 3 telephone calls, 
e-mails, fax, and, if necessary , a certified letter to the participant’s last known mailing address, 
or local equivale nt methods ). These contact attempts should be documented in the 
participant’s medical records.
Should the participant continue to be unreachable, they will be considered to have withdrawn 
from the study .
Should a study  site close, eg, for operational, financial, or other reasons, and the investigator cannot 
reach the participant to inform them, their contact information will be transferred to another stud y 
site.
7.4. National Disaster/Extra Ordinary  Circumstances
If appropriate, site visits may  be replaced with telephone visits during a national disaster or extra 
ordinary  circumstances, with site visits resuming as soon as possible thereafter. Telephone visits 
will be recorded in the source documentation and eCRF. If a visit included blood collection ,the 
collect ion and testing may  be done at a facility  closer to the participant . A copy  of the laboratory  
report, along with the reference ranges must be obtained for the source documentation and 
provided with the eCRF. Study  intervention may be dispensed by alternati ve methods (for example 
shipped to participant s). Refer to Section 10.12 , Appendix 12, Guidance on Study  Conduct during 
the COVID -19 Pandemic, for details related to the COVID pandemic that may also be applied to 
other national disasters or extra ordinary  circumsta nces.
8. STUDY ASSESSMENTS A ND PROC EDURES
Overview
The Schedule of Activities summarizes the frequency  and timing of efficacy , biomarker, safety
measurements applicable to this study .
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 30
Status: Approved ,  Date: 20 April 2021The PSA assessments should be conducted /completed before any tests, procedu res, or other 
consultations to prevent influencing participant perceptions .
Blood collections should be kept as close to the specified time as possible. Other measurements 
may be done earlier than specified timepoints if needed. Actual dates and times of assessments 
will be recorded in the source documentation and eCRF.
The total blood volume for the main study  is approximately  55mL.
Repeat or unscheduled samples may  be taken for technical issues with the samples.
Sample Collection and Handling
Refer to Section 1.3, Schedule of Activities for the timing and frequenc y of all sample collections.
Study -Specific Materials
The investigator will be provided with the following information :
IBand ERLEADA USPI for apalutamide and USPI  for ADT
Pharmacy  Manual/ Study Site Investigational P roduct and P rocedures M anual
National Cancer Institute Common -Terminology  Criteria for Adverse Events ( NCI-CTCAE )
Version 5.0
Response Evaluation Criteria in Solid Tumors ( RECI ST)guidelines Version 1.1
Electronic data capture ( eDC)Manual
eSource Manual
ICFtemplate
8.1. Efficacy  Assessments
Efficacy  assessments include serum PSA and testosterone and will be assessed prior to first dose 
of study  intervention and throughout the study  per the SoA. A PSA level >0.2 ng/mL  (confirmed 
within 3 -4 weeks) will be considered an indicator of BCR .
8.2. Safety  Assessments
Participants will be monitored for safet y from the beginning of the treatment and at each study  
visit. Events related to and associated with the recovery  from the pre-planned RPwill not be 
collected.
Details regarding the Steering Committee are provided in Committees Structure in Section 10.3
Appendix 3, Regulatory , Ethical, and Study  Oversight Considerations.
Adverse events will be reported and followed by the investigator as specified in Section 8.3, 
Adverse Events and Serious Adverse Events and Section 10.4, Appendix 4, Adverse Events, 
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 31
Status: Approved ,  Date: 20 April 2021Serious Adverse Events, Product Quality  Complaints, and Other Safet y Reporting: Definitions and 
Procedures for Recording, Evaluating, Follow- up, and Reporting .
Any clinicall y relevant changes occurring dur ing the study  must be recorded on the AEsection of 
the eCRF.
Any clinically  significant abnormalities persisting at the end of the stud y/early  withdrawal will be 
followed b y the investigator until resolution or until a clinically  stable condition is reach ed.
The study  will include the following evaluations of safet y and tolerability  according to the time 
points provided in the SoA .
8.2.1. Physical Examination s
Focused physical examinations including skin assessment will be completed prior to treatment, 
and at 2, 3,4, 7, 10, 13, and 14months. Focused examinations are generally  limited to the body 
systems or regions based on participant’s self -assessment and AE reporting. Any new complaints, 
symptoms reported by participants or adverse events noted by providers should guide the need and 
extent of phy sical examination.
8.2.2. Vital Signs
Vital signs are to be assessed per standard of care or as warranted b y AEs.
8.2.3. Electrocardiogram s
A 12-lead ECG will be conducted prior to treatment to assess for QT prolongation, if not available 
from pre-operative evaluation . During the collection of ECGs, participants should be in a quiet 
setting without distractions (eg, television, cell phones). Participants should rest in a supine 
position for at least 5minutes before ECG collection and should refrain from talking or moving 
arms or legs. If blood sampling or vital sign measurement is scheduled for the same time point as 
ECG recording, the procedures should be performed in the following order: ECG(s), vital signs, 
blood draw.
8.2.4. Clinical Safety  Laboratory  Assessments
Blood samples will be collected as noted in Section 10.2, Appendix 2, Clinical Laboratory  Tests. 
The investigator must review the laboratory  results, document this review, and record any 
clinically  relevant changes occurring during the study  in the AEsection of the eCRF. The 
laboratory  reports must be filed with the source documents. The only study-specified laboratory  
assessments are PSA and testosterone.
8.3. Adverse Events and Serious A dverse Events
Timely, accurate, and complete reporting and analy sis of safety  inform ation from clinical studies 
are crucial for the protection of participants, investigators, and the sponsor, and are mandated by 
regulatory  agencies worldwide. The sponsor has established Standard Operating Procedures in 
conformity  with regulatory  requireme nts worldwide to ensure appropriate reporting of safet y 
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 32
Status: Approved ,  Date: 20 April 2021information; all clinical studies conducted by the sponsor or its affiliates will be conducted in 
accordance with those procedures.
Adverse events will be reported by the participant (or, when appropr iate, by a caregiver, surrogate, 
or the participant's legally acceptable representative) for the duration of the study .
For further details on AEs and SAEs (Definitions and Classifications; Attribution Definitions; 
Severity  Criteria; Special Reporting Situations; Procedures) as well as product quality  complaints, 
refer to Section 10.4, Appendix 4, Adverse Events, Serious Adverse Events, Product Qualit y
Complaints, and Other Safet y Reporting: Definitions and Procedures for Recording, Evaluating, 
Follow -up, and Reporting .
8.3.1. Time Period and Frequency  for Collecting A dverse E vent and S erious 
Adverse E vent Information
All Adverse Events
Monitoring of AEs will be performed at 1, 2, 3, 4, 7, 10, 13, 14 months, at each follow -upvisit, 
and during phone calls with the participants. All AEs and special reporting situations, whether 
serious or non-serious, will be reported from the time after the participant receives the first dose 
of apalutamide until completion of the participant's last study -related procedure, which may 
include contact for follow -up of safet y. Serious adverse events, including those spontaneously  
reported to the investigator within 30days after the last dose of study intervention , must be 
reported using the SAE Form. The sponsor will evaluate any safety  information that is 
spontaneously  reported by  an investigator bey ond the time frame specified in the protocol.
Serious Adver se Events
All SAEs occurring during the study  must be reported to the appropriate sponsor contact person 
by study -site personnel within 24 hours of their knowledge of the event.
Information regarding SAEs will be transmitted to the sponsor using the SAE Form, which must 
be completed and signed by  a ph ysician from the study  site, and transmitted to the sponsor within 
24 hours. The initial and follow -up reports of a nSAE should be emailed to the to the appropriate 
sponsor contact person by  study -site personne l.
8.3.2. Method of Detecting A dverse E vents and S erious Adverse E vents
Care will be taken not to introduce bias when detecting AEs or SAEs . Open -ended and nonleading 
verbal questioning of the participant is the preferred method to inquire about AEoccurrence.
Participants who are not able to respond verball y, may be asked to write a brief description of 
how they  have been feeling.
8.3.3. Follow -up of A dverse E vents and S erious Adverse E vents
Adverse events, including pregnancy , will be followed by the investigator as specified in 
Section 10.4,Appendix 4Adverse Events , Serious Adverse Events, Product Quality  Complaints, 
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 33
Status: Approved ,  Date: 20 April 2021and Other Safet y Reporting : Definitions and Procedures for Recording, Evaluating, Follow -up, 
and Reporting.
8.3.4. Regulatory  Reporting Requirements for S erious Adverse E vents
The sponsor assumes responsibility  for appropriate reporting of AEto the regulatory  authorities. 
The sponsor will also report to the investigator (and the head of the investigational institute where 
required) all suspected unexpected serious adverse reactions (SUSARs). The investigator (or 
sponsor where required) must report SUSARs to the appropriate Independent Ethics 
Committee/I nstitutional Review Board (IEC/I RB) that approved the protocol unless otherwise 
required and documented by  the IEC/IRB.
The plan for monitoring and anal yzing the anticipated events is specified in the IB .
The sponsor assumes responsibility  for appropriate reporting of the listed anticipated events 
according to the United States requirements .
8.3.5. Pregnancy
All initial reports of pregnancy in partners of male participants must be reported to the sponsor b y 
the study -site personnel within 24 hours of their knowledge of the event using the appropriate 
pregnancy  notification form. Abnormal pregnancy  outcomes (eg, spontaneous abortion, fetal 
death, stillbirth, congenital anomalies, ectopic pregnancy ) are considered SAEs and must be 
reported using the SAE Form. Follow -up information regarding the outcome of the pregnancy and 
any postnatal sequelae in the infant wil l be required .
8.3.6. Cardiovascular and Death Events
Ischemic cardiovascular events, including events leading to death, occurred in patients receiving 
apalutamide. Monitor for signs and symptoms of ischemic heart disease. Optimize management of 
cardiovascular risk factors, such as hypertension, diabetes, or dyslipidemia. Consider 
discontinuation of apalutamide for Grade 3 and 4 events.
8.3.7. Disease -Related Events andDisease -Related Outcomes not 
Qualify ing as A dverse Eventsor Serious Adverse E vents
All events that meet the definition of a nSAE will be reported as SAEs , regardless of whether they 
are protocol -specific assessments.
Disease progression should not be recorded as an AEor SAE term; instead, signs and symptoms 
of clinical sequelae resulting from disease progression/lack of efficacy  will be reported if they 
fulfil the SAE definition (refer to Adverse Event Definitions and Classifications in Section 10.4, 
Appendix 4, Adverse Events, Serious Adverse Events, Product Quality  Complaints, and Other 
Safety  Reporting: Definitions and Procedures for Recording, Evaluating, Follow -up, and 
Reporting ). Expected progression of disease should not be considered an AE(or SAE ). However, 
if determined by the investigator to be more likely  related to the study intervention than the 
underly ing disease, the clinical signs or symptoms of progression and the possibility  that the study 
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 34
Status: Approved ,  Date: 20 April 2021intervention is enhancing disease progre ssion, should be reported per the usual reporting 
requirements.
8.3.8. Adverse Events of Special Interest
For apalutamide, there are no non -serious AEs of special interest identified.
Rash is an AE of special interest to be assessed by CTCAE criteria and following the specific rash 
management plan in Appendix 9, Recommendations for Management of Drug related Rash.
8.4. Pharmacokinetics (Not A pplicable)
8.5. Genetics
Genetics will be evaluated by DNA repair deficient (DRD )germline testing using whole blood 
sample .
8.6. Biomarkers
Biomarker samples may be collected as outlined in the SoA. Biomarker analysis is planned to 
retrospectivel y evaluate risk scores and other genomic markers and correlate with participants ’ 
response to treatment and explore HRD status and efficacy  of apalutamide in this subpopulation. 
To address these objectives, tumor tissue will be collected andsent to sponsor’s laboratory partner 
along with a copy of the full histopathology  report of the specimen. Biopsy tissue is required for
risk scores (Prolaris) and is preferred for HRD testing Also, whole blood and plasm a samples may
be collected at baseline, 12months or end of treatment, and at 24months or progression 
(whichever comes first) .
Stopping Analysis
Biomarker analyses are dependent upon the availability  of appropriate biomarker assay s and 
clinical response rates. Biomarker analysis may be deferred or not performed, if during or at the 
end of the study , it becomes clear that the analysis will not have sufficient scientific value for 
biomarker evaluation, or if there are not enough samples or responders to allow for adequate 
biomarker evaluation. In the event the study  is terminated early  or shows poor clinical efficacy , 
completion of biomarker assessments is based on justification and intended utility  of the data.
Additional Collections
If it is determined at any time before study  completion that additional material is needed from a 
formalin -fixed, paraffin- embedded tumor sample for the successf ul completion of the protocol 
specified analy ses, the sponsor may request that additional material be retrieved from existing  
samples. Also, based on emerging scientific evidence, the sponsor may request additional material 
from previously  collected tumor samples during or after study  completion for a retrospective 
analysis. In this case, such analyses would be specific to research related to the study 
intervention (s) or diseases being investigated.
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 35
Status: Approved ,  Date: 20 April 20218.7. Immunogenicity  Assessments (Not A pplicable)
8.8. Health Economi cs(Not A pplicable)
9. STATISTICA L CONSIDERA TIONS
Statistical analy sis will be done by the sponsor or under the authority  of the sponsor. A general 
description of the statistical methods to be used to anal yze the efficacy  and safet y data is outlined 
below. Sp ecific details will be provided in the Statistical Analy sis Plan.
9.1. Statistical Hy potheses
The primary  hypothesis of this study  is that adjuvant treatment with apalutamide andADT will 
improve the BCR -free rate at 24 months in the treatment -naïve , non -metas tatic prostate cancer 
population who are at high risk for the development of metastases compared to historical data 
without adjuvant treatment (76%) .14
9.2. Sample Size Determination
It is assumed that BCR -free rate follows an exponential distribution with a constant hazard rate. It 
is estimated that approximately  94 participants accrued over approximately  1 year, treated for 
12months and followed for an additional 12 months would be required to provide at least 
80% power in detecting a 10% absolute increase in BCR- free rate at 24 months of 76% to 86% at 
a 1-tailed significance level of 0.05. The null hypothesis of 76% BCR -free rate at 24 months for 
the historical data of no adjuvant treatment is an estimate based on published data.14Sample size 
was calculated using PASS 15 (Power Analy sis and Sample Size Software [2017]).20
9.3. Populations for A nalysis Sets
For analy sis purpose , the following sets are defined:
All safety anal yses will be performed using the Treated set. The Treated set will consist of all 
participants who received at least 1 dose of apalutamide.
All efficacy  anal yses will be performed using the Modified Intent -to-Treat set. The Modified 
Intent -to-Treat set consist of all participants who satisfy  all of the following: 
Met all eligibility  criteria and are enrolled in the study
Received at least 1 dose of apalutamide
Had a baseline PSA and at least 1 post -treatment PSA assessment.
9.4. Statistical A nalyses
The statistical analy sis plan will be finalized prior to database lock (DBL )and it will include a 
more technical and detailed description of the statistical analy ses described in this section. This 
section is a summary of the planned statistical analyses of the most important endpoints including 
primary  and key secondary  endpoint s.
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 36
Status: Approved ,  Date: 20 April 20219.4.1. General Considerations
Primary  endpoint test of hypothesis will be performed at 1-sided significant level 0.05; a 2-sided 
alpha level of 0.10 will be used to provide all confidence intervals.
9.4.2. Primary  Endpoint
Time to BCR (ie ,PSA >0.2 ng/mL) will be ana lyzed using Kaplan -Meier method. The BCR -free 
rate at 24 months will be estimated with the90% confidence interval. Null hypothesis of BCR
free-rate of 76% will be rejected if the lower limit of the 90% confidence interval exceeds 76%. 
Participants who d o not have any  occurrence of PSA >0.2 ng/mL , will be considered as censored 
at their last time of PSA measurement.
9.4.3. Secondary  Endpoint
The secondary  endpoint of testosterone recovery  will be analyzed similarly  to the primary 
endpoint. The testosterone recovery , defined asa serum testosterone ≥150 ng/dL, will be analyzed 
using Kaplan- Meier method. The testosterone recovery  at 24 months will estimated together with 
95% confidence interval.
9.4.4. Exploratory  Endpoint
Incidence of rash will be summarized descriptively .
9.4.5. Safety  Analyses
All safet y anal yses will be made on the Safet y Population.
Adverse Events
The verbatim terms used in the eCRF by investigators to identify  AEs will be coded using the 
Medical Dictionary  for Regulatory  Activities (MedDRA). AnyAE occurring at or after the initial 
administration of study  intervention through the day of last dose plus 30days is considered to be 
treatment emergent .All reported treatment emergent AEs will be included in the analysis. For each 
AE,the percentage o f participants who experience at least 1 occurrence of the given event will be 
summarized by  intervention group.
Summaries, listings, datasets, or participant narratives may  be provided, as appropriate, for those 
participants who die, who discontinue intervention due to an AE, or who experience a severe or a 
serious AE .
Parameters with predefined NCI-CTCAE toxicity  grades will be summarized. Change from 
baseline to the worst AEgrade experienced b y the participant during the study will be provided as 
shift tables.
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 37
Status: Approved ,  Date: 20 April 20219.4.6. Other A nalyses
Biomarkers Analyses
Participants with biomarker samples will be evaluated for high -risk genomic classifiers and HRD 
status. A subgroup analysis will be performed to assess the treatment effect in participants stratified 
by risk classifiers and HRD status.
The association of biomarkers with clinical response endpoints or survival may  be assessed using 
appropriate statistical methods (eg, analy sis of variance [ANOVA], categorical, or survival 
models) depending on the endpoints. Analy ses may be performed within and between each 
intervention group. Other clinical covariates (such as baseline tumor characteristics and participant
demographics) may also be included in the model. Association of biomarkers with clinica l 
response or relevant time-to-event endpoints will also be explored in the overall population. 
Results of these exploratory  anal yses will be presented in separate technical reports.
9.5. Interim A nalysis(Not A pplicable)
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 38
Status: Approved ,  Date: 20 April 202110. SUPPORTING DOCUMENTA TION A ND OPERA TIONAL CONSIDERA TIONS
10.1. Appendix 1: Abbrev iations
ADT androgen deprivation therapy
ADL Activities of Daily Living
AE adverse event
AR androgen receptor
ANOVA analysis of variance
BCR biochemical recurrence
BCR P breast cancer resistance protein
BSA body surface area
COVID -19 coronavirus disease 2019
CSPC castration -sensitive prostate cancer
CT computed tomography
CYP cytochrome P450
DBL database lock
DES diethylstilbestrol
DRD DNA repair deficient
ECG electrocardiogram
ECOG Eastern Cooperative Oncology Group
eCRF electronic case report form
eDC electronic data capture
EOS end of study
FDA Food and Drug Administration
FSH follicle stimulating hormone
GCP Good Clinical Practice
GnRH gonadotropin releasing hormon e
HRD homologous recombinant deficiency
HRT horm onal replacement therapy
IB investigator’s brochure
ICF informed consent form
ICH International Council for Harmonisation
ICMJE International Committee of Medical Journal Editors
IEC Independent Ethics Committee
IRB Institutional Review Board
IUD intrauterine device
IUS intrauterine hormone -releasing system
mCSPC metastatic castration -sensitive prostate cancer
MedDRA Medical Dictionary for Regulatory Activities
MRI magnetic resonance imaging
MFS metastasis -freesurvival
NCCN National Comprehensive Cancer Netw ork
NCI-CTCAE National Cancer Institute Common Terminology Criteria for Adverse Events
nmCRPC non-metastatic castration -resistant prostate cancer
OATP1B1 organic anion transporter 1B1
PET positron emission tomography
PASS Power Analysis and Sample Size Software
P-gp P-glycoprotein
PQC product quality complaint
PSA prostate -specific antigen
RECIST Response Evaluation Criteria in Solid Tumors
RP radical prostatectomy
rPFS radiographic progression free survival
SAE serious adverse event
SoA Schedule of Activities
SUSAR suspected unexpected serious adverse reaction
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 39
Status: Approved ,  Date: 20 April 2021UGT uridine diphosphate glucuronosyl transferase
USPI United States Package Insert
Definitions of Terms
Electronic source 
systemContains data traditionally maintained in a hospital or clinic record to document medical 
care or data recorded in a CRF as determined by the protocol. Data in this system may be 
considered source documentation.
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 40
Status: Approved ,  Date: 20 April 202110.2. Appendix 2: Clinical Laboratory  Tests
Prostate -specific antigen and testosterone tests will beperformed b y the local laborator y.
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 41
Status: Approved ,  Date: 20 April 202110.3. Appendix 3: Regulatory , Ethical, and Study Oversight Considerations
10.3.1. Regulatory  and Ethical Considerations
Investigator Responsibilities
The investigator is responsible for ensuring that the study  is performed in accordance with the 
protocol, current International Council for Harmonization (ICH) guidelines on Good Clinical 
Practice (GCP), and applicable regulatory  and country -specific requirements.
Good Clinical Practice is an international ethical and scientific qualit y standard for designing, 
conducting, recording, and reporting studies that involve the participation of human participants. 
Compliance with this standard provides public assurance that the rights, safety , and w ell-being of 
study  participants are protected, consistent with the principles that originated in the Declaration of 
Helsinki, and that the study  data are credible.
Protocol Amendments
Neither the investigator nor the sponsor will modify this protocol witho ut a formal amendment b y 
the sponsor . All protocol amendments must be issued by the sponsor , and signed and dated by  the 
investigator . Protocol amendments must not be implemented without prior IEC/IRB approval, or 
when the relevant competent authority  has raised any grounds for non-acceptance, except when 
necessary  to eliminate immediate hazards to the participants, in which case the amendment must 
be promptly  submitted to the IEC/IRB and relevant competent authority . Documentation of 
amendment approval b y the investigator and IEC/IRB must be provided to the sponsor . When the 
change(s) involve only logistic or administrative aspects of the study , the IEC/IRB (where 
required) onl y needs to be notified.
During the course of the study , in situations where a departure from the protocol is unavoidable, 
the investigator or other physician in attendance will contact the appropriate sponsor representative 
listed in the Contact Information page(s), which will be provided as a separate document. Except 
in emergency sit uations, this contact should be made before implementing any departure from the 
protocol. In all cases, contact with the sponsor must be made as soon as possible to discuss the 
situation and agree on an appropriate course of action. The data recorded in th e eCRF and source 
documents will reflect any departure from the protocol, and the source documents will describe 
this departure and the circumstances requiring it.
Regulatory Approval/Notification
This protocol and any amendment(s) must be submitted to the appropriate regulatory  authorities 
in each respective country , if applicable. A study may not be initiated until all local regulatory  
requirements are met.
Required Prestudy Documentation
The following documents must be provided to the sponsor before shipment of study  intervention
to the study  site:
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 42
Status: Approved ,  Date: 20 April 2021Protocol and amendment(s), if an y, signed and dated by the principal investigator
 A copy of the dated and signed (or sealed, where appropriate per local regulations), written 
IEC/IRB approval of the protocol, amendments, ICF, any recruiting materials, and if 
applicable, participant compensation programs. This approval must clearly identify  the 
specific protocol by title and number and must be signed (or sealed, where appropriate per 
local regulations) b y the cha irman or authorized designee.
 Name and address of the IEC/IRB, including a current list of the IEC/I RB members and their 
function, with a statement that it is organized and operates according to GCP and the 
applicable laws and regulations. If accompanied by a letter of explanation, or equivalent, from 
the IEC/I RB, a general statement may be substituted for this list. If an investigator or a 
member of the study -site personnel is a member of the IEC/IRB, documentation must be 
obtained to state that this perso n did not participate in the deliberations or in the vote/opinion 
of the study .
 Regulatory  authority  approval or notification, if applicable
 Signed and dated statement of investigator (eg, Form FDA 1572), if applicable
 Documentation of investigator qualifications (eg, curriculum vitae)
 Completed investigator financial disclosure form from the principal investigator, where 
required
 Signed and dated clinical trial agreement, which includes the financial agreement
 Any other documentation required by  local regulations
The following documents must be provided to the sponsor before enrollment of the first 
participant:
 Completed investigator financial disclosure forms from all subinvestigators
 Documentation of subinvestigator qualifications (eg, curriculum vita e)
 Name and address of any local laboratory  conducting tests for the study , and a dated copy  of 
current laboratory  normal ranges for these tests, if applicable
 Local laboratory  documentation demonstrating competence and test reliability  
(eg,accreditation/ license), if applicable
Independent Ethics Committee or Institutional Review Board
Before the start of the study , the investigator (or sponsor where required) will provide the IEC/I RB 
with current and complete copies of the following documents (as required by local regulations):
 Final protocol and, if applicable, amendments
 Sponsor -approved ICF (and any  other written materials to be provided to the participants)
 IB (or equivalent information) and amendments/addenda
 Sponsor -approved participant recruiting ma terials
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 43
Status: Approved ,  Date: 20 April 2021 Information on compensation for study -related injuries or payment to participants for 
participation in the study , if applicable
 Investigator's curriculum vitae or equivalent information (unless not required, as documented 
by the IEC/IRB)
 Informatio n regarding funding, name of the sponsor, institutional affiliations, other potential 
conflicts of interest, and incentives for participants
 Any other documents that the I EC/IRB requests to fulfill its obligation
This study  will be undertaken only after the IEC/IRB has given full approval of the final protocol, 
amendments (if any, excluding the ones that are purely  administrative, with no consequences for 
participants, data or study  conduct, unless required locall y), the ICF, applicable recruiting 
materials , and participant compensation programs, and the sponsor has received a copy of this 
approval. This approval letter must be dated and must clearl y identify the IEC/IRB and the 
documents being approved.
Approval for the collection of samples for research included in the ICF must be obtained from the 
IEC/IRB. Approval for the protocol can be obtained independent of this research component.
During the study  the investigator (or sponsor where required) will send the following documents 
and updates to the IEC/IR B for their review and approval, where appropriate:
 Protocol amendments (excluding the ones that are purely  administrative, with no 
consequences for participants, data or stud y conduct)
 Revision(s) to I CF and any  other written materials to be provided to participants
 If applicable, new or revised participant recruiting materials approved by  the sponsor
 Revisions to compensation for study -related injuries or payment to participants for 
participation in the study , if applicable
 New edition(s) of the IBand a mendments/addenda
 Summaries of the status of the study  at intervals stipulated in guidelines of the IEC/IRB (at 
least annuall y)
 Reports of AEs that are serious, unlisted/unexpected, and associated with the study  
intervention
 New information that may adversel y affect the safety of the participants or the conduct of the 
study
 Deviations from or changes to the protocol to eliminate immediate hazards to the participants
 Report of deaths of participants under the investigator's care
 Notification if a new investi gator is responsible for the study  at the site
 Development Safet y Update Report and Line Listings, where applicable
 Any other requirements of the IEC/I RB
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 44
Status: Approved ,  Date: 20 April 2021For all protocol amendments (excluding the ones that are purel y administrative, with no 
consequences for participants, data or study  conduct), the amendment and applicable ICF revisions 
must be submitted promptly to the IEC/IRB for review and approval before implementation of the 
change(s).
At least once a year, the IEC/I RB will be asked to review and reapprove this study , where required.
At the end of the study , the investigator (or sponsor where required) will notify  the IEC/IRB about 
the study  completion (if applicable, the notification will be submitted through the head of 
investigational institution).
Country Selection
This study  will only  be conducted in the US .
Other Ethical Considerations
For study -specific ethical design considerations, refer to Section 4.2.1 , Participant Input Into 
Design .
10.3.2. Financial Disclosure
Investigators and subinvestigators will provide the sponsor with sufficient, accurate financial 
information in accordance with local regul ations to allow the sponsor to submit complete and 
accurate financial certification or disclosure statements to the appropriate regulatory  authorities. 
Investigators are responsible for providing information on financial interests during the course of 
the study  and for 1 y ear after completion of the study .
Refer to Required Prestudy  Documentation (above) for details on financial disclosure.
10.3.3. Informed Consent Process
Each participant (or a legall y acceptable representative) must give written consent according to 
local requirements after the nature of the study  has been fully  explained. The ICF(s) must be signed 
before performance of any stud y-related activity . The ICF(s) that is/are used must be approved b y 
both the sponsor and by  the reviewing IEC/I RB and be in a language that the participant can read 
and understand. The informed consent should be in accordance with principles that originated in 
the Declaration of Helsinki, current ICH and GCP guidelines, applicable regulatory requirements, 
and sponsor policy .
Before enrollment in the study , the investigator or an authorized member of the study -site 
personnel must explain to potential participants or their legall y acceptable representatives the aims, 
methods, reasonabl y anticipated benefits, and potential hazar ds of the study , and any discomfort 
participation in the study  may entail. Participants will be informed that their participation is 
voluntary  and that they may withdraw consent to participate at any time. They  will be informed 
that choosing not to partici pate will not affect the care the participant willreceive for the treatment 
of his disease. Participants will be told that alternative treatments are available if they refuse to 
take part and that such refusal will not prejudice future treatment. Finall y,they will be told that 
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 45
Status: Approved ,  Date: 20 April 2021the investigator will maintain a participant identification register for the purposes of long-term 
follow up if needed and that their records may be accessed by health authorities and authorized 
sponsor personnel without violating the confidentiality  of the participant, to the extent permitted 
by the applicable law(s) or regulations. By signing the ICF the participant or legall y acceptable 
representative is authorizing such access, which includes permission to obtain information abou t 
his survival status. I t also denotes that the participant agrees to allow his or her study ph ysician to 
recontact the participant for the purpose of obtaining consent for additional safet y evaluations, and 
subsequent disease -related treatments, if needed .
The participant or legally  acceptable representative will be given sufficient time to read the ICF 
and the opportunity  to ask questions. After this explanation and before entry  into the study , consent 
should be appropriately recorded by means of either the participant's or his legally acceptable 
representative's personally  dated signature. After having obtained the consent, a copy of the ICF 
must be given to the participant.
10.3.4. Data Protection
Privacy of Personal Data
The collection and processing of personal data from participants enrolled in this study  will be 
limited to those data that are necessary  to fulfill the objectives of the stud y.
These data must be collected and processed with adequate precautions to ensure confidentialit y 
and compliance with applicable data privacy  protection laws and regulations. Appropriate 
technical and organizational measures to protect the personal data against unauthorized disclosures 
or access, accidental or unlawful destruction, or accidental loss or alteration must be put in place. 
Sponsor personnel whose responsibilities require access to personal data agree to keep the identity 
of participants confidential.
The informed consent obtained from the participant (or his or her legally  acceptable representative) 
include s explicit consent for the processing of personal data and for the investigator/institution to 
allow direct access to his or her original medical records (source data/documents) for study -related 
monitoring, audit, IEC/IRB review, and regulatory  inspection . This consent also addresses the 
transfer of the data to other entities and to other countries.
The participant has the right to request through the investigator access to his or her personal data 
and the right to request rectification of an y data that ar e not correct or complete. Reasonable steps 
will be taken to respond to such a request, taking into consideration the nature of the request, the 
conditions of the study , and the applicable laws and regulations.
Exploratory  biomarker research is not conduct ed under standards appropriate for the return of data 
to participants. In addition, the sponsor cannot make decisions as to the significance of any findings 
resulting from exploratory  research. Therefore, exploratory  research data will not be returned to 
participants or investigators, unless required by law or local regulations. Privacy  and
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 46
Status: Approved ,  Date: 20 April 2021confidentiality  of data generated in the future on stored samples will be protected by the same 
standards applicable to all other clinical data.
10.3.5. Long -Term Retention of S amples for A dditional Future Research
Samples collected in this study  may be stored for up to 15 y ears (or according to local regulations) 
for additional research. Samples will only be used to understand apalutamide with ADT , to 
understand localized high -risk prostate cancer , to understand differential intervention responders, 
and to develop tests/assay s related to apalutamide with ADT and localized high-risk prostate 
cancer . The research may begin at any  time during the study  or the post -study  storage period. 
Stored samples will be coded throughout the sample storage and analysis process and will not be 
labeled with personal identifiers. Participants may withdraw their consent for their samples to be 
stored for research (refer to Section 7.2.1 , Withdrawal From the Use of Research Samples ).
10.3.6. Committee Structure
Steering Committee
A Steering Committee will be established to provide guidance and supervision for the study , 
including ensuring the continued safet y of the participants enrolled in this study .Thecommittee 
chair will have medical expert isein the relevant therapeutic area. Committee membership 
responsibilities, authorities, and procedures will be documented in its charter.
10.3.7. Publication Policy /Dissemination of Clinical Study  Data
All information, including but not limited to information regarding apalutamide or the sponsor's 
operations (eg,patent application, formulas, manuf acturing processes, basic scientific data, prior 
clinical data, formulation information) supplied by the sponsor to the investigator and not 
previously  published, and any data, including biomarker research data, generated as a result of this 
study , are considered confidential and remain the sole property  of the sponsor. The investigator 
agrees to maintain this information in confidence and use this information only to accomplish this 
study  and will not use it for other purposes without the sponsor's prior w ritten consent.
The investigator understands that the information developed in the study will be used by the 
sponsor in connection with the continued development of apalutamide , and thus may be disclosed 
as required to other clinical investigators or regulatory  agencies. To permit the information derived 
from the clinical studies to be used, the investigator is obligated to provide the sponsor with all 
data obtained in the study .
The results of the study  will be reported in a Clinical Study  Report generat ed by the sponsor and 
will contain data from all study  sites that participated in the study  as per protocol. Recruitment 
performance or specific expertise related to the nature and the key assessment parameters of the 
study  will be used to determine a coordinating investigator for the study . Results of biomarker 
analyses performed after the Clinical Study  Report has been issued will be reported in a separate 
report and will not require a revision of the Clinical Study  Report. 
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 47
Status: Approved ,  Date: 20 April 2021Study  participant identifiers will not be used in publication of results. Any work created in 
connection with performance of the study  and contained in the data that can benefit from copyright 
protection (except an y publication by the investigator as provided for below) shall be the pr opert y 
of the sponsor as author and owner of cop yright in such work.
Consistent with Good Publication Practices and International Committee of Medical Journal 
Editors (ICMJE) guidelines, the sponsor shall have the right to publish such primary (multicenter ) 
data and information without approval from the investigator. The investigator has the right to 
publish study  site-specific data after the primary  data are published. If an investigator wishes to 
publish information from the study , a copy  of the manuscrip t must be provided to the sponsor for 
review at least 60 days before submission for publication or presentation. Expedited reviews will 
be arranged for abstracts, poster presentations, or other materials. If requested by the sponsor in 
writing, the investi gator will withhold such publication for up to an additional 60days to allow for 
filing of a patent application. In the event that issues arise regarding scientific integrity  or 
regulatory  compliance, the sponsor will review these issues with the investig ator. The sponsor will 
not mandate modifications to scientific content and does not have the right to suppress information. 
For multicenter study  designs and sub-study  approaches, secondary  results generall y should not 
be published before the primary  endpo ints of a study  have been published. Similarly , investigators 
will recognize the integrity  of a multicenter study  by not submitting for publication data derived 
from the individual study  site until the combined results from the completed study  have been 
submitted for publication, within 18months after the study  end date, or the sponsor confirms there 
will be no multicenter study publication. Authorship of publications resulting from this study  will 
be based on the guidelines on authorship, such as those described in the ICMJE Recommendations 
for the Conduct, Reporting, Editing and Publication of Scholarl y Work in Medical Journals, which 
state that the named authors must have made a significant contribution to the conception or design 
of the work; or the acq uisition, analy sis, or interpretation of the data for the work; and drafted the 
work or revised it critically  for important intellectual content; and given final approval of the 
version to be published; and agreed to be accountable for all aspects of the work in ensuring that 
questions related to the accuracy or integrity of any part of the work are appropriatel y investigated 
and resolved.
Registration of Clinical Studies and Disclosure of Results
The sponsor will register and disclose the existence of and the results of clinical studies as required 
by law. The disclosure of the final study  results will be performed after the end of study  in order 
to ensure the statistical analy ses are relevant.
10.3.8. Data Quality  Assurance
Data Quality Assurance/Quality Control
Steps to be taken to ensure the accuracy  and reliability  of data include the selection of qualified 
investigators and appropriate study  sites, review of protocol procedures with the investigator and
study -site personnel before the study , and periodic monito ring visits by the sponsor, and direct 
transmission of clinical laboratory  data from a central laboratory  into the sponsor's data base. 
Written instructions will be provided for collection, handling, storage, and shipment of samples. 
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 48
Status: Approved ,  Date: 20 April 2021The sponsor will review eCRF for accuracy  and completeness during on-site monitoring visits and 
after transmission to the sponsor; any discrepancies will be resolved with the investigator or 
designee, as appropriate. After upload of the data into the study  database they  will be verified for 
accuracy  and consistency with the data sources.
10.3.9. Case Report Form Completion
Case report forms are prepared and provided by the sponsor for each participant in electronic 
format. All data relating to the study  must be recorded in eCRF. All eCRF entries, corrections, and 
alterations must be made by the investigator or authorized study -site personnel. The investigator 
must verify  that all data entries in the eCRF are accurate and correct.
The study  data will be transcribed by study-site personnel from the source documents onto an 
eCRF, if applicable. Study -specific data will be transmitted in a secure manner to the sponsor.
Worksheets may be used for the capture of some data to facilitate completion of the eCRF. Any 
such worksheets will become part of the participant's source documents. Data must be entered into 
eCRF in English. The eCRF must be completed as soon as possible after a participant visit and the 
forms should be available for review at the next scheduled monitoring visit.
All participative measurements will be completed by the same individual who made the initial 
baseline determinations whenever possible.
If necess ary, queries will be generated in the eDC tool. I f corrections to an eCRF are needed after 
the initial entry  into the eCRF, this can be done in either of the following way s:
Investigator and study -site personnel can make corrections in the eDC tool at their own 
initiative or as a response to an auto query  (generated by  the eDC tool).
Sponsor or sponsor delegate can generate a query for resolution b y the investigator and stud y-
site personnel.
10.3.10. Source Documents
At a minimum, source documents consistent in the type and level of detail with that commonly  
recorded at the study  site as a basis for standard medical care must be available for the following: 
participant identification, eligibility , and study  identification; study  discussion and date of signed 
informed consent; dates of visits; results of safety and efficacy  parameters as required by the 
protocol; record of all AEs and follow -up of AEs ; concomitant medication; intervention
receipt/dispensing/return records; study  intervention administration information; and date of study  
completion and reason for early discontinuation of study  intervention or withdrawal from the 
study , if applicable. 
The author of an entry  in the source documents should be identifiable.
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 49
Status: Approved ,  Date: 20 April 2021Specific details required as source data for the study and source data collection methods will be 
reviewed with the investigator before the study and will be described in the monitoring guidelines 
(or other equivalent document).
The following data will be recorded directl y into the e CRF and will be considered source data :
Race
History  of smoking , all nicotine use, eg, cigarettes (including e -cigarettes or the equivalent of 
e-cigarettes), cigars, chewing tobacco, patch, gum
History  of alcohol intake, including type, usage, amount, and frequency .
Height and weight at baseline
The minimum source documentation requirements for Section 5.1, Inclusion Criteria and 
Section 5.2, Exclusion Criteria that specify a need for doc umented medical history  are as follows :
Referral letter from treating ph ysician or
Complete history  of medical notes at the site
Discharge summaries
Inclusion and exclusion criteria not requiring documented medical history must be verified at a 
minimum by participant interview or other protocol required assessment (eg, physical 
examination, laboratory  assessment) and documented in the source documents.
An eSource system may be utilized, which contains data traditionally  maintained in a hospital or 
clinic record to document medical care (eg, electronic source documents) as well as the clinical 
study -specific data fields as determined by the protocol. This data is electronically extracted for 
use by  the sponsor. If eSource is utilized, references made to the eCRF in the protocol include the 
eSource system but information collected through eSource may not be limited to that found in the e
CRF.
10.3.11. Monitoring
The sponsor will use a combination of monitoring techniques central, remote, or on-site monitoring
to monitor this study .
The sponsor will perform on-site monitoring visits as frequentl y as necessary . The monitor will 
record dates of the visits in a study  site visit log that will be kept at the study  site. The first 
post-initiation visit will be made as soon as possible after enrollment has begun. At these visits, 
the monitor will compare the data entered into the eCRF with the source documents 
(eg,hospital/clinic/phy sician’s office medical records). The nature and location of all source 
documents will be identified to ensure that all sources of original data required to complete the 
eCRF are known to the sponsor and study -site personnel and are accessible for verification by the 
sponsor study -site contact. If electronic records are maintained at the study  site, the method of 
verification must be discussed with the study -site personnel. 
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 50
Status: Approved ,  Date: 20 April 2021Direct access to source documents (medical records) must be allowed for the purpose of verifying 
that the recorded data are consistent with the original source data. Findings from t his review will 
be discussed with the study -site personnel. The sponsor expects that, during monitoring visits, the 
relevant study -site personnel will be available, the source documents will be accessible, and a 
suitable environment will be provided for review of study -related documents. The monitor will 
meet with the investigator on a regular basis during the study  to provide feedback on the study 
conduct.
In addition to on -site monitoring visits, remote contacts can occur. It is expected that during these
remote contacts, study- site personnel will be available to provide an update on the progress of the 
study  at the site .
Central monitoring will take place for data identified by  the sponsor as requiring central review.
10.3.12. On-site A udits
Representatives of thesponsor's clinical quality  assurance department may visit the study  site at 
any time during or after completion of the study  to conduct an audit of the study  in compliance 
with regulatory  guidelines and company  policy . These audits will require access to all study 
records, including source documents, for inspection. Participant privacy  must, however, be 
respected. The investigator and study -site personnel are responsible for being present and available 
for consultation during routinely  scheduled study -siteaudit visits conducted by  the sponsor or its 
designees. 
Similar auditing procedures may also be conducted by agents of any regulatory  body, either as part 
of a national GCP compliance program or to review the results of this study  in support of a 
regulat ory submission. The investigator sshould immediately  notify  the sponsor if they have been 
contacted b y a regulatory agency  concerning an upcoming inspection.
10.3.13. Record Retention
In compliance with the ICH/GCP guidelines, the investigator/institution will maintain all eCRF 
and all source documents that support the data collected from each participant, as well as all study 
documents as specified in I CH/GCP Section 8, Essential Documents for the Conduct of a Clinical 
Trial, and all study  documents as specified bythe applicable regulatory  requirement(s). The 
investigator/institution will take measures to prevent accidental or premature destruction of these 
documents.
Essential documents must be retained until at least 2years after the last approval of a marketing
application in an ICH region and until there are no pending or contemplated marketing applications 
in an I CH region or until at least 2 years have elapsed since the formal discontinuation of clinical 
development of the investigational product. These docum ents will be retained for a longer period 
if required by the applicable regulatory  requirements or by an agreement with the sponsor. It is the 
responsibility  of the sponsor to inform the investigator/institution as to when these documents no 
longer need to be retained.
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 51
Status: Approved ,  Date: 20 April 2021If the responsible investigator retires, relocates, or for other reasons withdraws from the 
responsibility  of keeping the study  records, custody  must be transferred to a person who will accept 
the responsibility . The sponsor must be notified in writing of the name and address of the new 
custodian. Under no circumstance shall the investigator relocate or dispose of any study documents 
before having obtained written approval from the sponsor.
If it becomes necessary  for the sponsor or the approp riate regulatory  authority  to review any 
documentation relating to this study , the investigator/institution must permit access to such reports.
10.3.14. Study and Site Start and Closure
First Act of Recruitment
The first site open is considered the first act of rec ruitment and it becomes the study  start date.
Study Termination
The sponsor reserves the right to close the study  site or terminate the study  at any time for any 
reason at the sole discretion of the sponsor. Study sites will be closed upon study  completion. A 
study  site is considered closed when all required documents and study  supplies have been collected 
and a stud y-site closure visit has been performed.
The investigator may initiate study -site closure at any time, provided there is reasonable cause and 
sufficient notice is given in advance of the intended termination.
Reasons for the earl y clo sure of a study  site by the sponsor or investigator may include but are not 
limited to:
Failure of the investigator to comply  with the protocol, the requir ements of the IEC/IRB or 
local health authorities, the sponsor's procedures, or GCP guidelines
Inadequate recruitment of participants by  the investigator
Discontinuation of further study  intervention development
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 52
Status: Approved ,  Date: 20 April 202110.4. Appendix 4: Adverse Events, Serious A dverse Events, Product Quality  
Complaints, and Other Safety  Reporting: Definitions and Procedures for 
Recording, Evaluating, Follow- up, and Reporting
10.4.1. Adverse Event Definitions and Classifications
Adverse Event
An AE is any untoward medical occurrence in a clinical study  participant administered a medicinal 
(investigational or non-investigational) product. An AEdoes not necessarily  have a causal 
relationship with the intervention . An AEcan therefore be any unfavorable and unintended sign 
(including an abnormal finding), symptom, or disease temporally  associated with the use of a 
medicinal (investigational or non-investigational) product, whether or not related to that medicinal 
(investigational or non-investigational) product. (Definition per International Counc ilfor
Harmonisation [I CH]10)
This includes any  occurrence that is new in onset or aggravated in severit y or frequency  from the 
baseline condition, or abnormal results of diagnostic procedures, including laboratory  test 
abnormalities.
Note: The sponsor collects AEs from the time after the participant receives the first dose of 
apalutamide (refer to All Adverse Events under Section 8.3.1 , Time Period and Frequency  for 
Collecting Adverse Events and Serious Adverse Events Information, for time of last AE
recording).
Serious Adverse Event
An SAE based on ICH and EU Guidelines on Pharmacovigilance for Medicinal Products for 
Human Use is an y untoward medical occurrence that at an y dose:
Results in death
Is life -threatening
(The participant was at risk of death at the time of the event. It does not ref er to an event that 
hypothetically  might have caused death if it were more severe.)
Requires inpatient hospitalization or prolongation of existing hospitalization
Results in persistent or significant disability /incapacity
Is a congenital anomal y/birth defe ct
Is a suspected transmission of an y infectious agent via a medicinal product
Is Medicall y Important*
*Medical and scientific judgment should be exercised in deciding whether expedited reporting is 
also appropriate in other situations, such as important m edical events that may not be immediatel y 
life threatening or result in death or hospitalization but may jeopardize the participant or may 
require intervention to prevent one of the other outcomes listed in the definition above. These 
should usually  be con sidered serious.
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 53
Status: Approved ,  Date: 20 April 2021If a serious and unexpected AEoccurs for which there is evidence suggesting a causal relationship 
between the study  intervention and the event (eg, death from anaph ylaxis), the event must be 
reported as a serious and unexpected suspected adverse reaction even if it is a component of the 
study  endpoint (eg, all -cause mortality ). 
Unlisted (Unexpected) Adverse Event/Reference Safety Information
An AEis considered unlisted if the nature or severity is not consistent with the applicable produ ct 
reference safet y information. Forapalutamide , the expectedness of an AEwill be determined by 
whether or not it is listed in the IB.
10.4.2. Attribution Definitions
Assessment of Causality
The causal relationship to study  intervention is determined by the Investigator. The following 
selection should be used to assess all AE.
Related
There is a reasonable causal relationship between study  intervention administration and the AE.
Not Related
There is not a reasonable causal relationship between study  intervention administration and the 
AE.
The term "reasonable causal relationship" means there is evidence to support a causal relationship.
10.4.3. Severity Criteria
An assessment of severity  grade will be made using the Common Terminology  Criteria for 
Adverse Events (CTCAE) Version 5.0, where ‘grade’ refers to the severit y of the AE .
Grade 1 Mild; asy mptomatic or mild sy mptoms; clinical or diagnostic observations only ; 
intervention not indicated
Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age 
appropriate instrumental Activities of Daily  Living (ADL)
Grade 3 Severe or medically significant but not immediately  life-threatening; 
hospitalization or prolongation of hospitalization indicated; disabling; limiting 
self-care (ADL)
Grade 4 Life-threatening consequences; urgent intervention indicated.
Grade 5 Death related to AE.
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 54
Status: Approved ,  Date: 20 April 2021For additional information, refer to Common Terminology  Criteria for Adverse Events (CTCAE) 
Version 5.0 Published: November 27, 2017 .
10.4.4. Special Reporting Situations
Safety  events of interest on a sponsor study  intervention in an interventional study that may require 
expedited reporting or safety  evaluation include, but are not limited to:
Overdose of a sponsor study  intervention
Suspected abuse/misuse of a sponsor study  intervention
Accidental or occupational exposure to a sponsor study  intervention
Medication error, intercepted medication error, or potential medication error involving a 
Johnson & Johnson medicinal product (with or without participant exposure to the Johnson & 
Johnson medicinal product, eg, product name confusion, product label confusion, intercepted 
prescribing or dispensing errors )
Exposure to a sponsor study  intervention from breastfeeding
Special reporting situations should be recorded in the eCRF. Any special reporting situation that 
meets the criteria of a nSAE should be recorded on the SAE page of the eCRF.
10.4.5. Procedures
All Adverse Events
All AEs, regardless of seriousness, severit y, or presumed relationship to study  intervention , must 
be recorded using medical terminology  in the source document and the eCRF. Whenever possible, 
diagnoses should be given when signs and symptoms are due to a common etiology  (eg,cough, 
runny  nose, sneezing, sore throat, and head congestion should be reported as "upper respiratory  
infection"). Investigators must record in the eCRF their opinion concerning the relationship of the 
AEto study  therap y. All measures requi red for AEmanagement must be recorded in the source 
document and reported according to sponsor instructions.
For all studies with an outpatient phase, including open -label studies, the participant must be 
provided with a "wallet (study ) card" and instruct ed to carry  this card with them for the duration 
of the study  indicating the following: 
Study  number
Statement, in the local language(s), that the participant is participating in a clinical study
Investigator's name and 24-hour contact telephone number
Local sponsor's name and 24 -hour contact telephone number (for medical personnel only)
Site number
Participant number
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 55
Status: Approved ,  Date: 20 April 2021Serious Adverse Events
All SAEs that have not resolved by the end of the study , or that have not resolved upon 
discontinuation of the partic ipant's participation in the study , must be followed until any of the 
following occurs:
The event resolves
The event stabilizes
The event returns to baseline, if a baseline value/status is available
The event can be attributed to agents other than the stud y intervention or to factors unrelated 
to study  conduct
It becomes unlikely  that any additional information can be obtained (participant or health care 
practitioner refusal to provide additional information, lost to follow -up after demonstration of 
due dil igence with follow -up efforts)
Suspected transmission of an infectious agent by  a medicinal product will be reported as a nSAE . 
Any event requiring hospitalization (or prolongation of hospitalization) that occurs during the 
course of a participant's partic ipation in a study  must be reported as anSAE , except 
hospitalizations for the following:
Hospitalizations not intended to treat an acute illness or AE (eg, social reasons such as pending 
placement in long -term care facility )
Surgery  or procedure planned b efore entry into the study  (must be documented in the eCRF). 
Note: Hospitalizations that were planned before the signing of the ICF, and where the 
underly ing condition for which the hospitalization was planned has not worsened, will not be 
considered SAEs .Any AE that results in a prolongation of the originall y planned 
hospitalization is to be reported as a new SAE .
For convenience the investigator may choose to hospitalize the participant for the duration of 
the intervention period.
Expected progression of disease should not be considered an AE(or SAE ). However, if determined 
by the investigator to be more likely  related to the study  intervention than the underl ying disease, 
the clinical signs or symptoms of progression and the possi bility  that the study  intervention is 
enhancing disease progression, should be reported per the usual reporting requirements.
10.4.6. Product Quality  Complaint Handling
A product quality  complaint (PQC) is defined as any suspicion of a product defect related to 
manufacturing, labeling, or packaging, ie, any dissatisfaction relative to the identity , quality , 
durability , or reliability of a product, including its labeling or package integrity. A PQC may  have 
an impact on the safet y and efficacy of the product. Timely, accurate, and complete reporting and 
analysis of PQC information from studies are crucial for the protection of participants, 
investigators, and the sponsor, and are mandated by regulatory  agencies worldwide. The sponsor 
has established procedures in conformit y with regulatory  requirements worldwide to ensure 
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 56
Status: Approved ,  Date: 20 April 2021appropriate reporting of PQC information; all studies conducted by the sponsor or its affiliates will 
be conducted in accordance with those procedures.
Procedures
All initial PQCs must be reported to the sponsor by  the study -site personnel within 24 hours after 
being made aware of the event .
If the defect is combined with anSAE , the study -site personnel must report the PQC to the sponsor 
according to the SAE reporting timelines (refer to Section 8.3.1 , Time Period and Frequency  for 
Collecting Adverse Event and Serious Adverse E vent Information). A sample of the suspected 
product should be m aintained for further investigation if requested by  the sponsor.
10.4.7. Contacting Sponsor Regarding Safety , Including Product Quality
The names (and corresponding telephone numbers) of the individuals who should be contacted 
regarding safet y issues, PQC, or questions regarding the study  are listed in the Contact Information 
page(s), which will be provided as a separate document.
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 57
Status: Approved ,  Date: 20 April 202110.5. Appendix 5: Contraceptive Guidance
Participants’ female partners must follow contraceptive measures as outlined as below . Pregnancy 
information will be collected and reported as noted in Section 8.3.5 , Pregnancy and Section 10.4, 
Appendix 4Adverse Events, Serious Adverse Events, Product Quality  Complaints, and Other 
Safety  Reporting: Definitions and Procedures for Recording, Evaluating, Follow -up, and 
Reporting.
Definitions
Woman of Childbearing Potential (WOCBP)
A woman is considered fertile following menarche and until becoming postmenopausal unless 
permanentl y sterile (see below).
Woman Not of Childbearing Potential
premenarchal
A premenarchal state is one in whic h menarche has not y et occurred.
postmenopausal
A postmenopausal state is defined as no menses for 12 months without an alternative medical 
cause. A high follicle stimulating hormone (FSH) level (>40 IU/L or mIU/mL) in the 
postmenopausal range may be used to confirm a postmenopausal state in women not using 
hormonal contraception or hormonal replacement therapy  (HRT), however in the absence of 
12months of amenorrhea, a single FSH measurement is insufficient.
permanently sterile
Permanent sterilization methods include hysterectomy , bilateral salpingectomy , bilateral tubal 
occlusion/ligation procedures, and bilateral oophorectomy .
Note : If the childbearing potential changes after start of the study  (eg, a premenarchal woman
experiences menarche) or the riskof pregnancy  changes (eg, a woman who is not heterosexually  
active becomes active), a woman must begin a highl y effective method of contraception, as 
described throughout the inclusion criteria.
If reproductive status is questionable, additional evaluatio n should be considered.
Contraceptive (birth control) use by men or women should be consistent with local regulations 
regarding the acceptable methods of contraception for those participating in clinical studies.
Typical use failure rates may differ from those when used consistently  and correctl y. Use should 
be consistent with local regulations regarding the use of contraceptive methods for participants in 
clinical studies.
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 58
Status: Approved ,  Date: 20 April 2021Examples of Contraceptives
EXAMPLES OF CONTRACEPTIVESaALLOWED DURING THE STUDY INCLUDE:
USER INDEPENDENT
Highly Effective Methods That Are User Independent Failure rate of <1% per year when used 
consistently and correctly.
Implantable progestogen -only hormone contraception associated with inhibition of ovu lationb
Intrauterine device (IUD)
Intrauterine hormone -releasing system (IUS)
Bilateral tubal occlusion
Vasectomized partner
(Vasectomized partner is a highly effective contraceptive method provided that the partner is the 
sole sexual partner of the woman of childbearing potential and the absence of sperm has been 
confirmed. If not, additional highly effective method of contraception should be used. 
Spermatogenesis cycle is approximately 74 days.)
USER DEPENDENT
Highly Effective Methods That Are User Dependent Failure rate of <1%  per year when used 
consistently and correctly.
Combined (estrogen- and progestogen- containing) hormonal contraception associated with 
inhibition of ovulationb
oral
intravaginal
transderm al
injectable
Progestogen -only hormone contraception associated with inhibition of ovulationb
oral
injectable
Sexual abstinence
(Sexual abstinence is considered a highly effective method only if defined as refraining from 
heterosexual intercourse during the entire period of risk associated with the study intervention. 
The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study 
and the preferred and usual lifestyle of the participant.)
NOT ALLOWED AS SOLE METHOD OF CONTRACEPTION DURING THE STUDY (not 
considered to be highly effective -failure rate of 1% per year)
Progestogen -only oral hormonal contraception where inhibition of ovulation is not the primary 
mode of action.
Male or female condom with or without spermicidec
Cap, diaphragm, or sponge with spermicide
A combination of male condom with either cap, diaphragm, or sponge with spermicide (double -
barrier methods)c
Periodic abstinence (calendar, symptothermal, post -ovulation methods)
Withdrawal (coitus -interruptus)
Spermicides alone
Lactational amenorrhea method
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 59
Status: Approved ,  Date: 20 April 2021aTypical use failure rates may differ from those when used consistently and correctly. Use should be 
consistent with local regulations regarding the use of contraceptive methods for participants in 
clinical studies.
bHormonal contraception may be susceptib le to interaction with the study intervention, which may 
reduce the efficacy of the contraceptive method. In addition, consider if the hormonal contraception 
may interact with the study intervention.
cMale condom and female condom should not be used toget her (due to risk of failure with friction).
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 60
Status: Approved ,  Date: 20 April 202110.6. Appendix 6: Prohibited Concomitant Medic ations
Apalutamide
Drugs known tolower theseizure threshold orcause seizures areprohibited andarepresentative
listisincluded below:
Aminophy lline/theophy lline
Atypical antipsy chotics (eg ,clozapine, olanzapine, risperidone, ziprasidone)
Bupropion
Lithium
Meperidine (pethidine)
Phenothiazine antipsy chotics (eg, chlorpromazine, mesoridazine, thioridazine)
Tricy clicantidepressants (eg,amitripty line, desipramine, doxepin, imipramine, maprotiline,
mirtazapine)
Other prohibited therapies include the following:
Investigational agents
Any other prior or current treatment for prostate cancer which includes but not limited to
Abiraterone acetate or other CYP17 inhibitors
Other hormonal agents for the treatment of prostate cancer
Other antineoplastic agents
Radiation therapy  
5-α-reductase inhibitors
Chemotherapy
Immunotherapy  or vaccine therapy for cancer treatment
Other anti-androgens (eg, bicalutamide, nilutamide, flutamide, cyproterone acetate,
enzalutamide)
Bisphosphonates ordenosumab unless for management of osteoporosis 
Systemic ketoconazole (or other azole drugs such as fluconazole or itraconazole)
Diethy lstilbestrol (DES) or similar
Other preparations such aspomegranates or pomegranate juice orsaw palmetto, which
arethought to have endocrine effects on prostate cancer
Radiopharmaceuticals such asstrontium (89Sr)orsamarium (153Sm) orsimilar analogs
such as radium -223(223Ra)
Spironolactone
If the permissibility of a specific drug/treatment is in question, please contact the sponsor.
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 61
Status: Approved ,  Date: 20 April 202110.7. Appendix 7: Restricted Concomitant Medications
Investigators should refer totheIB(Sections 4.3.4 and5.10) and associated addenda for
complete details onthedrug interaction potential ofapalutamide .
Medications that inhibit CYP2C8 or CYP3A4: Co-administration of a strong CYP2C8 or 
CYP3A4 inhibitor is predicted to increase the stead y-state exposure of the active moieties 
(sum of unbound apalutamide plus the potency -adjusted unbound N -desmethy l apalutamide ).
Noinitial dose adjustment isnecessary ;however, consider reducing theapalutamide dose
based onindividual tolerability .Mild ormoderate inhibitors of CYP2C8 or CYP3A4 are not 
expected to affect the exp osure of apalutamide.
Effect of apalutamide on drug metabolizing enzymes: Apalutamide is a strong inducer of 
CYP3A4 and CYP2C19, and a weak inducer of CYP2C9 in humans. Concomitant use of 
apalutamide with medications that are primarily metabolized by CYP3A 4, CYP2C19, or 
CYP2C9 can result in lower exposure to these medications. Substitution for these medications 
is recommended when possible or evaluate for loss of efficacy  if medication is continued. 
Concomitant administration of apalutamide with medications that are substrates of uridine 
diphosphate glucuronos yl transferase (UGT) can result in decreased exposure. Use caution if 
substrates of UGT must be co-administered with apalutamide and evaluate for loss of efficacy .
Effect of apalutamide on drug transpor ters: Apalutamide was clinically  shown to be a weak 
inducer of P -glycoprotein (P -gp), breast cancer resistance protein (BCRP), and organic anion 
transporter 1B1 (OATP1B1). Concomitant use of apalutamide with medications that are 
substrates of P-gp, BCRP, or OATP1B1 can result in lower exposure of these medications. 
Use caution if substrates of P-gp, BCRP, or OATP1B1 must be co-administered with 
apalutamide, and evaluate for loss of efficacy  if medication is continued.
Long -term use of systemically  administe red corticosteroids during the study  is not allowed. 
Short -term use (≤4 weeks, including taper) and locally  administered steroids (eg, inhaled, 
topical, ophthalmic, and intra -articular) are allowed, if clinically indicated. 
See Section 10.8, Appendix 8, Medications with the Potential for Drug -drug Interactions, for 
a complete list of medications prohibited while on active treatment with apalutamide.
Because of the potential for drug- drug interaction, the concurrent use of all other drugs, over -
the-counter medications, and alternative therapies must be documented on the eCRF. The 
principal investigator should be alerted if the participant is taking any agent found in Appendix 
(a listing of medications with the potential for drug- drug interaction).
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 62
Status: Approved ,  Date: 20 April 202110.8. Appendix 8: Medications with the Potential for Drug -drug Interactions
Generic Name Brand Name**
aminophy lline Aminocont; Aminomal; Diaphy llin; Filotempo; Neophy llin; 
Norph yl; Phy llocontin; Sy ntophy llin; Tefamin; Truphy lline; Xing 
You Shan; 
aminophy lline in 
combinationAsmeton; Cha Xin Na Min; Emergent-Ez; Fufang Dan An Pian; 
Ke Zhi
amitripty line Amirol; Amitrip; Amixide; Deprelio; Diapatol; Elatrol; cElatrolet; 
Elavil; Endep; Enovil; Emitrip; Klotripty l; Laroxy l; Levate; 
Limbitrol; L imbitry l; Mutabase; Mutabon; Nobritol; Novo -Tripty n; 
Pertripty l; Redomex; Saroten; Sarotex; Sedans; Sy neudon; 
Teperin; Tript izol; Triptyl; Tryptizol
amitripty line in 
combination PMS -Levazine
bupropion Aplenzin; Buproban; Contrave; Elontril; Forfivo; Fortivo XL; Le 
Fu Ting; Prexaton; Quomem; Voxra; Wellbutrin; Wellbutrin XL ; 
Wellbutrin SR; Yue Ting; Zy ban
chlorpromazine Aminazin; Chlorazin; Hibernal; Klorproman; Largactil; Megaphen; 
Ormazine; Plegomazin; Solidon; Tarocty l;Thorazine; Vegetamin; 
Wintermin; Zuledin
Note: in Ireland also called “Clonazine” – very easy  to confuse 
with clozapine.
clozapine Azaleptin; Clopine; Closastene; Clozaril; CloZAPine; Denzapine; 
Elcrit; Fazacio ODT; Klozapol; Lanolept; Leponex; L ozapine; 
Nemea; Ozapim; Sy nthon, Versacloz; Zaponex
desipramine Deprexan; Norpramin; Nortimil; Pertofrane
doxepin Adapin; Anten; Aponal; Deptran; Gilex; L i Ke Ning; Quitaxon; 
Silenor; Sinepin; Sinequan; Zonalon
imipramine Impril; Melipramin; Mipralin; Norfranil; Novo -Pramine; 
Persamine; Pertofram; Pryleugan; Talendep; Tofranil; Tolerade
lithium Arthriselect; Camcolit; Carbolith; Carbolithium; Eskolith; 
Hypnorex; L i-Liquid; L icarbium; L imas; L iskonum; L itarex; 
Lithane; Lithicarb; L ithioderm; L ithionit; L ithobid; L iticarb; 
Litiomal; L ito; Maniprex; Neurolepsin; Plenur; Priadel; 
Quilonorm; Quilonum; Saniquiet; Sedalit; Teralithe
lithium in combination Boripharm No 23; Emser Salz; Girheulit HOM; Helidonium -Plus; 
Heweurat N; rheuma -loges; Rhus Toxicodendron Compose; Rhus-
Plus; Ricinus Compose
maprotiline Cronmolin; Deprilept; Ludiomil; Mapromil; Melodil; Neuomil; 
Psymion
meperidine/pethidine Alodan; Atropin e and Demerol; Centralgine; Demerol; Dolantin ; 
Dolantina; Dolantine; Dolargan; Dolcontral,; Dolestine ; Dolosal ; 
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 63
Status: Approved ,  Date: 20 April 2021Generic Name Brand Name**
Dolsin; Fada; Hospira; Liba; Mepergan ; Meprozine,; Mialgin,; 
Opystan; Pethidine ; Petigan Miro ; Ps yquil compositum
meperidine/pethidine in
combination Pamergan P100
mesoridazine Serentil, Mesorin
mirtazapine Arintapin; Avanza; Axit; Combar; Esprital; Mi Er Ning; Miro; 
Mirta TAD; Mirtabene; Mirtachem; Mirtadepi; Mirtagamma; 
Mirtalan; MirtaL ich; Mirtamy lan; Mirtaron; Mirtaz; Mirtazelon; 
Mirtazon; Mirtazonal; Mirtel; Mirtin; Mirtor; Mirzaten; Norset; 
Noxibel; Paidisheng; Psidep; Remergil; Remergon; Remeron; 
Remirta; Rexer; Yarocen; Zispin
olanzapine Anzorin, Arenbil; Arkolamy l; Aty zyo; Bloonis; Clingozan; 
Egolanza; Lans yn; Lanzek; Lazapix; Nolian; Nykob; Olafid; 
Olanzaran; Olanzep; Olanzin; Olanzine; Olapin; Olasy n; Olazax; 
Olpinat; Olzapin; Olzin; Ou Lan Ning; Ozilormar; Parnassan; 
Ranofren; Sanza; Sty gapon; Sy nza; Ximin; Zalasta; Zamil; Zappa; 
Zapris; Zerpi; Zolafren; Zolaxa; Zona pir; Zopridoxin; Zy lap; 
Zypadhera; Zy pine; Zy prexa; Zy prexa Relprew; Zy dis
olanzapine in 
combination Symbyax
risperidone Aleptan; Apo- Risperid; Arketin; Calmapride; Diaforin; Doresol; 
Hunperdal; Jing Ping; Ke Tong; Leptinorm; Lergitec; Orizon; 
Ozidal; Pe rdox; Ranperidon; Resdone; Ridal; Ridonex; Rileptid; 
Ripedon; Risepro; Rispa; Rispaksole; Rispefar; Rispemy lan; 
Rispen; Rispera; Risperanne; Risperdal; Risperdalconsta; 
Risperdaloro; Risperigamma; Risperon; Rispolept; Rispolux; 
Rispond; Rispons; Risset; Ri xadone; Rorendo; Ryspolit; Si L i Shu; 
Sizodon; Speridan; Suo Le; Torendo; Zhuo Fei; Zhuo Fu; Ziperid; 
Zoridal
theophy lline Aerolate; Afonilum; Aminomal; An Fei Lin; Apnecut; Apo- Theo; 
Asmalix; Asmalon; Bi Chuan; Bronchoparat; Bronchoretard; 
Cylmin; Diffum al; Elixifilin; Elixophy llin; Etipramid; Euphy llin; 
Euphy llina; Euphy lline; Euphy long; Frivent; Gan Fei Lin; Nuelin; 
Protheo; Pulmophy lline; Quelesu; ratio -Theo -Bronc; Respicur; 
Retafy llin; Shi Er Ping; Slo -Bid; Slo- Phyllin; Telbans; Teotard; 
Terdan; Terom ol; Theo- 24; Theo -Dur; Theo; Theochron; Theodur; 
Theofol; Theolair; Theoplus; Theospirex; Theostat ; Theotard; 
Theotrim; Theovent; Tromphy llin; Unicon; Unicontin; Unify l; 
Uniphy l; Uniphy llin Continus; Uniphy llin; UniXan; Xanthium; Xi 
Fu L i; Yan Er
theophy lline in 
combinationAntong; Baladex; Bi Chuan; Binfolipase; Broncho -Euphy llin; 
Broncomar; Do- Do ChestEze; Elixophy llin-GG; Elixophy llin-KI; 
Insanovin; Marax ; Neoasma; Theofol Comp; Theophedrinum -N; 
Xu Hong; Yi Xi Qing
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 64
Status: Approved ,  Date: 20 April 2021Generic Name Brand Name**
thioridazine Detril; Elperil; Melleril; Ridazin; Ridazine; Thiodazine; Thioril; 
Sonapa
ziprasidone Geodon; L i Fu Jun An; Pramaxima; Si Bei Ge; Ypsila; Zeldox; 
Zipwell; Zy psila; Zy psilan
**Note: This document is intended as an aid in identifying prohibited meds but may not be all incl usive .
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 65
Status: Approved ,  Date: 20 April 202110.9. Appendix 9: Recommendations for Management of Drug- related Rash
In the combined data of two randomized, placebo -controlled clinical studies, rash associated 
with apalutamide was most commonly  described as macular or maculopapular. (Please refer 
to the current IB-for further details.)
Evaluate causality  of the rash ie,Is it related to apalutamide? Or another form of rash such as 
shingles, sunburn, etc.
If not considered related to apalutamide, evaluate and treat according to the etiology .
If possibl y related to apalutamide, grade the severit y of rash per the 
NCI-CTCAE Version 5.0 below and treat according to Dose Modification and 
Management Guidelines.
Rash 
maculo-papularA disorder characterized by  the presence of macules (flat) and papules 
(elevated). Also known as morbilli form rash, it is one of the most 
common cutaneous adverse events, frequentl y affecting the upper trunk, 
spreading centripetally and associated with pruritis .
Grade 1 Macules/papules covering <10% body  surface area ( BSA )with or without 
symptoms (eg, pruritus, burning, tightness) 
Grade 2 Macules/papules covering 10 to 30% BSA with or without sy mptoms (eg, 
pruritus, burning, tightness); limiting instrumental Activities of Daily  
Living (ADL); rash covering >30% BSA with or without mild sy mptoms .
Grade 3 Macules/papules covering >30% BSA with moderate or severe s ymptoms; 
limiting self -care ADL.
NCI-CTCAE Version 5.0; Published: 27 November 2017.
Toxicity Severity Dose Modification andManagement Guidelines
If there is blistering or mucosal involvement, stop apalutamide immediatel y and contact the sponsor .
Standardized photography  to be undertaken by  the study -site personnel. Educate on gentle skin care.
Initiate dermatological treatment .
Grade 1
or 
Grade 2Continue apalutamide atthe same dose :
oHigh potency  topical steroid lotion bid
eg, fluocinonide 0.05%, clobetasol 0.05%, or betamethasone 0.05% AND
oOral antihistamines hy droxy zine:
10 mg bid for Grade 1 or 25 mg bid for Grade 2, or equivalent.
Monitor forchange inseverity, contact the participant at minimum every 2 weeks :
oIf rash is stable or improves, continue current management and monitoring until rash 
resolves .
oIf rash worsens, follow guidance for Grade 3 .
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 66
Status: Approved ,  Date: 20 April 2021Toxicity Severity Dose Modification andManagement Guidelines
If there is blistering or mucosal involvement, stop apalutamide immediatel y and contact the sponsor .
Standardized photography  to be undertaken by  the study -site personnel. Educate on gentle skin care.
Initiate dermatological treatment .
Grade 3 Hold apalutamide until rash is Grade <1
oOral steroids Prednisone 0.5 to 1mg/kg/day  for 20 days or equivalent with maximum 
dose of 100 mg/day  AND
oHigh potency  topical steroid lotion or solution bid
eg, fluocinonide 0.05%, clobetasol 0.05%, or betamethasone 0.05% AND
oOral antihistamines (h ydrox yzine 25 mg bid or equivalent) .
oReassess after 2 weeks (by  site staff) .
After 2 weeks of management (as above): 
If the rash is the same or has worsened
oContinue to hold apalutamide and refer the participant to a dermatologist .
If rash improves to Grade 2: 
oCont inue to hold apalutamide, continue current management .
oReassess after 1 week (by site staff) .
After 1 week:
oIf after 1- week rash is still Grade 2, continue to hold apalutamide and refer the 
participant to a dermatologist .
oIf rash has improved to Grade <1, see below. 
If rash is Grade <1: 
oReinitiate apalutamide at half the dose (120 mg) for 2 weeks 
oContinue oral antihistamines for 1 week 
oStart tapering oral steroids 
oContinue topical treatment until rash resolves
oReturn to full dose after 2 weeks of ha lf dose apalutamide and if rash remains <1
If the proposed total oral steroid use will exceed 28 day s, contact the sponsor .
If after 28 day s of starting the treatment, rash has not resolved to Grade ≤1, contact the 
sponsor
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 67
Status: Approved ,  Date: 20 April 202110.10. Appendix 10: Phone calls with Pa rticipants
It is recommended to use a standardized questionnaire as noted below during phone calls. The 
questions serve as a guidance for documenting presence and severity of rash. All participants will 
receive a call weekl y in the first month of treatment and then mid-cycle (ie ,biweekl y) after Visit 2 
through Visit 3 and thereafter if theparticipant has rash (per Section 10.9, Appendix 9, 
Recommendations for Management of Drug -related Rash ). Participants should be encouraged to 
call the study  site any time they  notice a rash or if the rash worsens.
Guide for discussion during phone calls:
Askif the participant is willing to continue the study
Collect information on the participant ’scompliance with oral administration of study  
intervention
Collect information on the participant ’scurrent health status including discussion of 
concomitant medications and adverse events including an y skin rash
Have you noticed an y skin rash since the start of the treatment (or since the last site visit 
or phone call)? 
oIf this is the first occurrence of rash, please schedule a site visit f or the pa rticipant as 
soon as possible
If yes, do you have any symptoms associated with the rash? (eg,pruritus, tingling, 
burning, tightness)
What is the severity  of the sy mptoms? (none, mild, moderate, severe, very  severe)
Are the s ymptoms improving or w orsening?
(If applicable) Have you been regularl y appl ying the skin lotion or solution prescribed to 
you for skin rash?
Remind the participant about the gentle skin care instructions
Schedul e the next call (if applicable)
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 68
Status: Approved ,  Date: 20 April 202110.11. Appendix 11: Instructions for Gentle Skin Care
1.Light emollient (lotion) applied daily  as required after any  other prescribed topical steroid 
lotion has had time to dry.
2.Use an antiseptic -containing soap substitute or a mild pH -neutral soap (eg, Cetaphil) .
3.Avoid strong sun and weather e xtremes.
4.Use sunblock (SPF 50) when outdoors.
5. Avoid long, hot baths, showers and saunas. Use tepid water for bathing.
6.Avoid alcohol -based and fragranced skin -care products as these may  exacerbate dry  skin.
7.For participant s with pre-existing eczema: intensi fy usual skin care routine.
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 69
Status: Approved ,  Date: 20 April 202110.12. Appendix 12: Guidance on Study  Conduct during the COVID -19 Pandemic
The measures outlined in this appendix are temporary, while access to sites may be 
restricted. As restrictions are lifted, the decision to revert back to the protocol specified 
procedures should be discussed and agreed with the sponsor .
It is recognized that the Coronavirus Disease 2019 (COVID -19) pandemic may  have an impact on 
the conduct of this clinical study due to, for example, self -isolation/quarantine by  participants and 
study -site personnel; travel restrictions/limited access to public places, including hospitals; study  
site personnel being reassigned to critical tasks.
In alignment with recent health authority  guidance, the sponsor is providing options for study  
related participant management in the event of disruption to the conduct of the study . This guidance 
does not supersede any local or government requirements or the clinical judgment of the 
investigator to protect the health and well- being of partic ipants and site staff. If, at any time, a 
participant’s safet y is considered to be at risk, the study  intervention will be discontinued, and 
study  follow -up will be conducted.
If a potential participant had RP surger y delay ed due to the COVID -19 situation and was given 
ADT as a bridging measure until theparticipant could be scheduled for surgery , theparticipant
may still be considered for the study , if all other inclusion/exclusion criteria are met. Each 
individual case will need to be discussed with the study  sponsor for approval prior to entry  into 
the study .
Scheduled visits that cannot be conducted in person at the study  site will be performed to the extent 
possible remotel y/virtually  or delayed until such time that on-site visits can be resumed. At each 
contact, participants will be interviewed to collect safety data. Key efficacy endpoint assessments 
should be performed if required and as feasible. Participants will also be questioned regarding 
general health status to fulfill any  physical examinati on requirement.
Every  effort should be made to adhere to protocol -specified assessments for participants on study 
intervention, including follow -up. Modifications to protocol -required assessments may be 
permitted after consultation between the participant and investigator, and with the agreement of 
the sponsor. Missed assessments/visits will be captured in the clinical trial management system for 
protocol deviations. Discontinuations of study  interventions and withdrawal from the study  should 
be documented with the prefix “COVID -19-related” in the eCRF.
The sponsor will continue to monitor the conduct and progress of the clinical study , and any 
changes will be communicated to the sites and to the health authorities according to local guidance. 
If a participa nt has tested positive for COVID -19, the investigator should contact the sponsor’s 
responsible medical officer to discuss plans for study  intervention and follow -up. Modifications 
made to the study  conduct as a result of the COVID -19 pandemic should be summarized in the 
clinical study  report.
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 70
Status: Approved ,  Date: 20 April 2021GUIDANCE SPECIFIC TO THIS PROTOCOL: 
To ensure participant safety  and minimize disruption to completion of protocol scheduled visits, 
we recommend the following when it is not safe to complete a scheduled visit at the site due to the 
coronavirus pandemic: 
Arrange an appointment to conduct the visit as well as collect information on the participant
current health status, adverse events and concomitant medications over the phone or other 
remote technology  (Facetime, WhatsApp etc) as allowed by  local regulations. 
Document all communication with participant s and protocol related activities completed 
remotely  in the source and eDC as required. 
Document all missed assessments, discontinuations of study  interventions and withdrawal 
from the study . Missed assessments will be captured in the clinical trial management sy stem 
for protocol deviations, with the actual visit date documented or reason for withdrawals 
specified; discontinuations of study  interventions and withdrawal from the study  will be 
captured with the prefix “COVID -19-RELATED” in the eCRF.
Safety and Disease Evaluation Visits :
Protocol required laboratory  tests may be performed at a nearb y hospital or doctor´s office when 
they cannot be done at the site.
For participant s who are unable or unwilling to leave their homes to complete protocol 
scheduled visits due to the coronavirus pandemic, the visits should be postponed until it is 
deemed safe to return to the site or local hospital. 
It is strongly  recommended to schedule regular phone consultations to assess any new/ongoing 
adverse events including skin rash, fatigue, seizures, falls and fractures. Participant s should 
be encouraged to check their blood pressure at home regularl y and report any new symptoms 
to the study  team urgently . Advise participant s to seek immediate medical attention if any 
symptoms suggestive of a cardiovascular event occur .
If a participant is unable to visit study  site or designated laboratory , serum PSA and 
testosterone testing can be done at a local laboratory . Protocol required biomarker and 
pharmacogenomics sampling can be done at the site as soon as the situation permits.
Please ensure any evaluations are documented in the source and eDC. Identify the assessments 
as “missed or delay ed due to COVID -19”.
Changes in S tudy Intervention: 
Study  intervention (apalutamide) should be continued in the protocol specified manner. If a 
participant is unable to receive the drug as specified in the protocol, please call the sponsor to 
discuss. 
Androgen Deprivation Therap y (ADT) which is administered concurrentl y should be 
continued (1-month or 3-month depot formulations given intramuscular or subcutaneousl y per 
the information in the package insert). If a participant is unable to visit the study  site, please 
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 71
Status: Approved ,  Date: 20 April 2021arrange a visit to a nearby  hospital or doctor´s office or a home visit by  a trained provider to 
administer the ADT at home.
Keep C ommunications Open (within- site, sponsor -site, site -participant ):
Please maintain up-to-date contact information for one another (site colleagues, sponsor 
contacts, participant s) and keep communication channels open, including in circumstances 
where site staff/participants are experiencing restrictions in physical workplace or study  visit 
attendance.
Source Data Verification/Monitoring: 
On-site monitoring visits may not be possible due to local regulations, restrictions and 
guidance. In these cases, the Site Manager will arrange to conduct site monitoring visits and 
activities remotely . Additional on -site monitor ing visits may  be needed in the future to catch 
up on source data verification.
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 72
Status: Approved ,  Date: 20 April 202110.13. Appendix 13: Sub-Study Protocol
10.13.1. Protocol Summary
A sub-study  will be conducted assessing the coadministration of apalutamide and relugolix in 
treatment -naïve participants who have undergone radical prostatectomy  (RP) for non-metastatic 
prostate cancer and who are at high risk for metastases.
Apalutamide (ERL EADA®) is an orally  available, non-steroidal, small molecule, which acts as a 
potent and selective antagonist of androgen receptors (ARs). Apalutamide is indicated for the 
treatment of patients with non-metastatic castration -resistant prostate cancer (nmCRPC) and 
metastatic castration -sensitive prostate cancer (mCSPC). Patients should also receive a 
gonadotropin -releasing ho rmone (GnRH) analog concurrentl y or should have had a bilateral 
orchiectom y.
Relugolix (ORGOVY X™) is an orall y available GnRH receptor antagonist approved by the FDA 
on December 18, 2020 for the treatment of adult patients with advanced prostate cancer.
Given the recent approval of relugolix andthe fact that apalutamide is indicated in combination 
with a GnRH analog, there isaneed to understand the effect of combining relugolix and 
apalutamide on testosterone suppression.
This is a single -arm, open -label, multi- center sub-study  of apalutamide and relugolix in 
12participants with high risk localized prostate cancer who are treatment naïve, documented to 
have no evidence of metastatic disease prior to study  entry, who are between Day 29 and 
Day 90post-RP, whose PSA is ≤0.2 ng/mL  at study  entry , and who have recovered from surgery , 
per the clinical judgment of the investigator. There will be one stud y intervention group receiving 
relugolix monotherap y for 2 weeks followed by coadministration with apalutamide for 1 cycle 
(28days). Serum testosterone will be measured on Day –14 (ie,the day of starting relugolix 
administration), Day 1(ie, the day of starting coadministration with apalutamide) , and Day 28. 
The primary  endpoint is the percent age ofparticipant s maintaining testosterone <50ng/dL through 
Day 28, and the secondary  endpoint is safet y (adverse events )through Day 28. Upon completion 
of the sub-study , participant s will be transitioned into the main ApaRP study  protocol beginning 
at Cy cle 2 Day 1.
Refer to subsequent sections for details on objectives and endpoints, hypothesis, overall design, 
number of participants, intervention groups and duration, efficacy  evaluations, and safety 
evaluations.
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 73
Status: Approved ,  Date: 20 April 202110.13.2. Schema
Figure 2: Schematic Overview of the Sub-Study
[STUDY_ID_REMOVED]
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 75
Status: Approved ,  Date: 20 April 2021bThe sub-study ICF must be signed before first study -related activity and will cover the sub-study and the main 
study .
cRelugolix administered as 360 mg on first day of treatment (Day –14), follow ed by  120 mg on subsequent days.
dIf not occurring during an in-person visit, the study team should call the participant to ask about medication 
compliance.
eShould be completed daily by the participant during sub-study treatment and provided to the study team at each 
sub-study visit (form located i nSection 10.14 ,Appendix 14 ).
fIf participant's testosterone ≥50ng/dL on Day 1 or Day 28, stop relugolix, switch to intram uscular ADT, and 
switch to main ApaRP study .
gFocused examinations are generally limited to the body  system  or regions based on participant's self-assessment 
and AE reporting. Any new complaints, symptoms reported by participants or adverse events noted by providers 
should guide the need and extent of physical examination.
hCollected at baseline, 12 months or end of treatment, and at 24 months or progression (whichever comes first) as 
part of the main ApaRP study.
iTissue sample to be collected and sent to sponsor's laboratory partner along with a copy of the full histopathology 
report of the specimen. See Section 8.6for further details.
jCollection of concomitant therapies does not begin until time of first dose of relugolix.
kCollection of AEs does not begin until time of first dose of relugolix.
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 76
Status: Approved ,  Date: 20 April 202110.13.4. Introduction
10.13.4.1. Study Rationale
Relugolix (ORGOVYX™) is an orally available gonadotropin-releasing hormone (GnRH) 
receptor antagonist approved by the FDA on December 18, 2 020 for the treatment of adult patients 
with advanced prostate cancer. Relugolix is administered at a loading dose of 360 mg on the first 
day of treatment, followed by  120 mg taken orall y once dail y.Relugolix is metabolized primarily 
by CYP3A and is a substrate for intestinal P -glycoprotein (P-gp). Clinical studies with rifampin, a 
combined P -gp and strong CYP3A inducer ,decreased the AUC and C maxof relugolix by  55% and 
23%, respectivel y. Consequently , the relugolix label suggests avoiding coadministration with 
combined P-gp and strong CYP3A inducers and if unavoidable, to increase the dose of relugolix 
to 240 mg once daily .19
Apalutamide is a strong inducer of CYP3A4 and a weak inducer of P-gp. Concomitant use of 
apalutamide with medications that are primarily  metabolized by CYP3A4 and/or a substrate of 
P-gp can result in lower exposure of these medications. Apalutamide has been shown to reach 
steady state concentrations at 4 weeks .7
Given relugolix is the first and onl y approved oral GnRH antagonist and apalutamide is indicated 
in combination with a GnRH analog , there isaneed to understand the clinical implications of 
combining relugolix and apalutamide in the clinic. Achieving and maintaining a castrate level of 
serum testosterone (<50 ng/dL) while on ADT is considered the gold standard assessment of
achieving castration with GnRH analogs . Data from 899 participants (from Phase 1, 2, and 3 
studies) with both relugolix and testosterone concentration data were combined for PopPK and 
PopPK/PD analy ses.18In simulated testosterone concentrations, relugolix dosed as low as 40 mg 
once daily  following a loading dose of 360 mg achieved a median testosterone <50ng/dL within 
10 days.18Relugolix dosed at 120 mg once daily following a loading dose of 360 mg achieved a 
testosterone <50ng/dL in 90% of the simulations within 10days.18In the registrational Phase 3 
HERO study  of relugolix dosed at 120mg once daily  after a loading dose of 360 mg, the 
cumulative probability  of testosterone suppression to <50 ng/dL on Day 4 and Day 15 were 56% 
and 98.7%, respectivel y.24
As part of the Phase 3 HERO study , concomitant medications that could possibly  affect 
testosterone were tracked. Seventeen (3%) participants received concomitant enzalutamide with 
relugolix.19Similar to apalutamide, enzalutamide is a strong CYP3A4 inducer .30Invitro, 
enzalutamide and N-desmethy l enzalutamide are inhibitors of P-gp.30Despite the potential 
drug-drug interaction, no clinically  significant differences in the pharmacokinetics of relu golix 
were observed when coadministered with enzalutamide .19Additionally , no clinicall y relevant 
differences were noted in the incidence or types of adverse events (AE) before or after concomitant 
use of enzalutamide .18
Given the similarities in the metabolism of apalutamide and enzalutamide and the fact that 
relugolix achieved a median testosterone <50ng/dL within 10 days dosedas low as 40 mg once 
daily  following a loading dose of 360 mg, we hypothesize coadministration of apalutamide 240mg 
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 77
Status: Approved ,  Date: 20 April 2021once daily  with relugolix as indicated (120 mg once daily  following a loading dose of 360mg) 
will achieve and maintain castrate testosterone levels (<50 ng/dL) without the need to increase the 
relugolix dose.
For the most comprehensive nonclinical and clinical information regarding relugolix or 
apalutamide , refer to the latest versio n of the ir respective US Package Inserts (USPI ). 
10.13.4.2. Benefit -Risk A ssessment
More detailed information about the known and expected benefits and risks of apalutamide may 
be found in the ERLEADA®USPI .7More detailed information about the known and expected 
benefits and risks of relugolix may  be found in the ORGOVYX™USPI .19
The perceived benefit of relugolix is the convenience of oral administration versus intramuscular 
injections that require supervision of a physician as indicated with other GnRH analogs .
Throughout the course of this 6-week sub-study , serum testosterone levels will be assessed on 
multiple occasions and participant s will be removed from the sub-study  if castrate levels of 
testosterone are not achieved. Safet y will be monitored by AEreporting .With established safet y 
profiles, close monitoring, and the low risk of short -term reduced relugolix effect on testosterone , 
the benefit of assessing the coadministration of apalutamide and relugolix outweighs the potential
risks associated with each inte rvention.
10.13.5. Objectives and Endpoints
Objectives Endpoints
Primary
 To assess if the addition of apalutamide torelugolix 
is able to maintain castrate levels of testosterone. Percent age of pa rticipant s maintaining  
testosterone <50ng/dL through Day 28 .
Secondary
 To evaluate the safety of coadministering 
apalutamide and relugolix at their indicated doses. Adverse events through D ay 28 .
HYPOTHESIS
The primary  hypothesis of this sub-study  is that coadministration of apalutamide 240 mg once 
daily  with relugolix 120 mg once daily (following a loading dose of 360 mg) will achieve and 
maintain castrate levels of testosterone (<50 ng/dL).
10.13.6. SUB -Study Design
10.13.6.1. Overall Design
This is a single -arm, open -label, multi- center sub-study  of apalutamide and relugolix in 
12participants with high risk localized prostate cancer who are treatment naïve, documented to 
have no evidence of metastatic disease prior to study  entry, who are between Day 29 and Day 90
post-RP, whose PSA is ≤0.2 ng/mL at study  entry , and who have recovered from surgery , per the 
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 78
Status: Approved ,  Date: 20 April 2021clinical judgment of the investigator. Upon completion of the sub-study, participant s will be 
transitioned into the main ApaRP study  protocol beginning at C ycle 2 Day 1. 
The sub-study  will be conducted in approximately  6urology  practices already  conducting the main 
ApaRP study . There will be one study  intervention group receiving relugolix monotherapy for 
2weeks followed bycoadministration with apalutamide for 1 cycle (28 days). Treatment with 
relugolix will start following screening and completion of RP and no later than postoperative 
Day 90. Coadministration of apalutamide will start 14 days after initiation of relugolix 
monotherap y. Serum testosterone will be measure d on Day –14 (ie, day of starting relugolix 
administration) , Day  1(ie, the day  of starting coadministration with apalutamide), and Day  28. I f 
a participant doesnot achieve a serum testosterone <50ng/dL  on Day 1 following 14 days of 
relugolix monotherap y, relugolix will be discontinued and the participant will switch to 
intramuscular ADT and the main ApaRP study and that participant will be replaced in the 
sub-study . If a participant achieve sa serum testosterone <50 ng/dL on Day  1 following 14 da ys of 
relugolix monotherapy , coadministration with apalutamide will begin. As assessed on Day 28, if 
the coadministration of apalutamide and relugolix achieves and maintains a serum testosterone 
<50ng/dL through Day  28 of the sub -study , participant s will be given the opportunity  to continue 
relugolix and apalutamide as part of the main ApaRP study . If the coadministration of apalutamide 
and relugolix does not achieve and maintain a testosterone <50ng/dL through Day 28 of the 
sub-study in 2 or more participant s, all participants on the sub-study  will discontinue relugolix and 
switch to intramuscular ADT plus apalutamide as part of the main ApaRP study .
The sub-study  will have 12participants. If 2or more participants have a testosterone ≥50ng/dL
onDay 28, the sub-study  will be considered negative and all participant s will switch to 
intramuscular ADT inthe main ApaRP protocol. If 0 or 1participant hasa testosterone ≥50ng/dL, 
the sub- study  will continue until all 12 participants have been enrolled .
If a participant ends the sub-study  early (ie,due to treatment non-compliance or not achieving a 
testosterone <50 ng/dL on Day  1 after relugolix monotherap y), that participant will be replaced in 
order to enroll 12 pa rticipants total. If the sub -study  is terminate d early due to lack of efficacy (ie ,
≥2 participants have a testosterone ≥50ng/dL  on Day 28) or safet y (ie,≥2 participants have 
prolonged QTc (>ULN) on Day  28), no further participants will be enrolled intothe sub- study .
The timing and frequencies of study assessments are presented in the sub-study  SoA 
(Section 10.13.3 ,Appendix 13). Efficacy  assessments include serum testosterone and will be 
assessed at baseline (Day -14),after 14 day s of relugolix monotherapy (Day  1),and after 28 day s 
of coadministration of apalutamide and relugolix. A serum testosterone <50ng/dL is considered 
castrate and the gold standard for indicating castration while on ADT .Study enrollment is defined 
as the day when the participant receives the first dose of relugolix monotherapy  after having met 
all prescreening criteria. Adverse events will be assessed continuously  from the time of enrollment 
and during treatment. A 12 -lead electrocardiogram (ECG) will be conducted at screening, after 14 
days of relugolix monotherap y, and after 28 days of apalutamide and relugolix coadministration, 
to examine QT prolongation. If any participant has a prolonged QTc at either Day 1 or Day 28,
that participant will be removed from the study completely  and replaced in the sub-study . If 
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 79
Status: Approved ,  Date: 20 April 20212participant s have prolonged QTc at Day 28 the sub-study  will terminate dand any participants
currentl y on the combination of relugolix and apalutamide will be evaluated for potentiall y 
changing to intramuscular ADT.
A diagram of the stud y design is provided in Section 10.13.2 , Appendix 13, Schema. 
10.13.6.2. Scientific Rationale for Study  Design
The single -arm, open -label design is appropriate to evaluate the pharmacod ynamic effect of a new 
oral ADT medication with apalutamide. Additionally , stopping rules can be quickly  implemented 
with this design (see Section 10.13.6.1 , Appendix 13 Overall Design for stopping rules).
Scientific Rationale for the main ApaRP study  design can be found in Section 4.2, Scientific 
Rationale of the main protocol.
10.13.6.3. Justification for Dose
The dose of 240 mg on ce daily  apalutamide and 120 mg once daily  relugolix following a loading 
dose of 360 mg relugolix are ap proved doses per their respective USPIs.
10.13.6.4. End of Study  Definition
End of Study Definition
The sub-study  EOS is defined as the date of the last participant’s enrollment in the sub-study 
+6weeks or discontinuation of all study  participants from the sub-study , whichever occurs first. 
All pa rticipants will be transitioned to the main ApaRP study  following the sub -study  EOS visit.
Study Completion Definition
Participant swill be considered to have completed the sub-study  if they have completed EOS 
assessments. Participants who prematurel y discontinue sub-study  intervention for any reason 
before sub-study  completion will not be considered to have completed the sub-study . If a 
participant misses a dose for ≥3 days, the investigator should consult the sponsor regarding 
continuation of the sub -study .
10.13.7. Study Population
The sub -study  population will use the criteria of the main ApaRP study . Refer to Section 5of the 
main ApaR P protocol for details of the study  population .Participants must also be willing to 
participate in the sub -study  and should not have any allergy , hypersensitivity , or contraindications
to the administration of relugolix per the ORGOVYX USPI .
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 80
Status: Approved ,  Date: 20 April 202110.13.8. Study Interve ntion
10.13.8.1. Study Intervention Administered
Apalutamide
The sub-study  intervention apalutamide, 240 mg (four 60 mg tablets, slightly yellowish togreyish
green oblong film-coated tablets, debossed with “AR 60” on one side), will be provided as tablets 
for oral administration. Participants will be instructed to take their assigned dose of the sub-study  
intervention orally  once daily  for 28 daysper the ERLEADA USPI. Apalutamide can be taken 
with or without food. If a partic ipant experiences a ≥Grade 3 toxicity  or an intolerable side effect, 
hold dose until s ymptoms improve to ≤Grade 1 or original grade, then resume at the same dose or 
a reduced dose (180 mg or 120 mg), if warranted. If a participant remains off apalutamide for 
≥3days, the participant may be withdrawn from the sub-study and switched to the main ApaRP 
study after discussing with the sponsor. Participants experiencing treatment related seizure of an y 
grade will have apalutamide permanentl y discontinued.
Relugol ix
The sub-study  intervention relugolix , 120 mgwith a loading dose of 360 mg (three 120 mg tablets, 
light red, almond -shaped, film-coated, debossed with “R” on one side and “120” on the other side) , 
will be provided as tablets for oral administration. Participants will be instructed to take their 
assigned dose of the sub-study  intervention orally  once daily  for 42 daysperthe ORGOVYX
USPI . Relugolix can be taken with or without food. If a participant misses relugolix for ≥3 days, 
the participant may be withdrawn from the sub-study and switched to the main ApaRP study after 
discussing with the sponsor. 
Description of Interventions
Sub-study intervention sadministration must be captured in the source documents and the 
electronic case report form (eCRF). Sub-study  site personnel will instruct participants on how to 
store sub- study  intervention sfor at -home use as indicated for this protocol.
Apalutamide will be manufactured and provided under the responsibility  of the sponsor. Refer to 
the IB11for a list of excipients and the ERL EADA USPI .
Relugolix , anFDA approved and commerciall y available oral ADT, not provided by the sponsor , 
will be administered per the ORGOVYX USPI during the sub -study  and the main ApaRP study if 
participants continue relugolix coadministration (see Section 10.13.6.1 , Appendix 13, Overall 
Design for details of relugolix continuation in the main ApaRP study ). For further information on 
relugolix refer to the ORGOVYX USPI .For a definition of apalutamide overdose, refer to Section 
6.7, Treatment of Overdose, in the main ApaRP protocol.
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 81
Status: Approved ,  Date: 20 April 202110.13.8.2. Preparation/Handling/Storage/A ccou ntability
Preparation/Handling/Storage
Refer to the respective USPI sfor guidance on apalutamide and relugolix preparation, handling, 
and storage.
Accountability
The investigator is responsible for ensuring that all sub- study  interventions received at the site are
inventoried and accounted for throughout the sub-study . The sub-study  intervention sadministered 
to the participant must be documented on the intervention accountability  form. All sub-study 
interventions will be stored and disposed of according tothe sponsor’s instructions. Sub-study  site 
personnel must not combine contents of the sub -study  intervention containers.
Sub-study  interventions must be handled in strict accordance with the protocol and the container 
labels, and must be stored at the sub-study  site in a limited -access area or in a locked cabinet under 
appropriate environmental conditions. Unused sub-study  interventions and sub-study  interventions 
returned by the participant must be available for verification by the sponsor's study  site monitor 
during on-site monitoring visits. The return to the sponsor of unused sub-study  interventions, or 
used returned sub-study interventions for destruction, will be documented on the intervention 
return form. When the sub -study  site is an authorized destruction unit and sub-study  intervention 
supplies are destro yed on-site, this must also be documented on the intervention return form.
Sub-study  interventions should be dispensed under the supervision of the investigator or a qualified 
member of the study -site personnel, or by a hospital/clinic pharmacist. Sub-study  interventions 
will be supplied only to participants participating in the sub-study . Returned sub-study  
interventions must not be dispensed again, even to the same participant. Sub-study  interventions 
may not be relabeled or reassigned for use b y other participants. The investigator agrees neither to 
dispense the sub-study  intervention from, nor store it at, any site other than the sub-study  sites 
agreed upon with the sponsor. Further guidan ce and information for the final disposition of unused 
sub-study  interventions are provided in the Study  Site Investigational Product and Procedures 
Manual.
10.13.8.3. Study Intervention Compliance
Sub-study  site personnel will maintain a log of all sub-study  interve ntions dispensed. Sub-study  
interventions supplied for each participant will be inventoried and accounted for.
10.13.8.4. Dose Modification
Any dose adjustment should be overseen b y medically qualified study -site personnel (principal or 
sub-investigator unless an imm ediate safet y risk appears to be present).
In case a dose modification of apalutamide is necessary , apalutamide will be administered per
ApaRP main protocol Section 10.9, Appendix 9, Recommendations for Management of 
Drug -related Rash.
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 82
Status: Approved ,  Date: 20 April 202110.13.8.5. Treatment of Overdose
Refer to the main ApaRP protocol Section 6.7, Treatment of Overdose.
10.13.8.6. Conc omitant Therapy
Concomitant therapies must be recorded throughout the sub-study  from the time of first dose of 
sub-study  intervention (Day  -14) to the last sub-study  visit(Day  28). Concomitant therapies 
occurring after sub-study EOS will be captured as pa rt of the main ApaRP protocol (Section 6.8, 
Concomitant Therap y).
All therapies (prescription or over-the-counter medications, including vaccines, vitamins, herbal 
supplements; non-pharmacologic therapies such as electrical stimulation, acupuncture, special 
diets, exercise regimens, or other specific categories of intere st) different from the sub-study  
intervention must be recorded in the eCRF. Recorded information will include a description of the 
type of therapy , duration of use, dosing regimen, route of administration, and indication. 
Modification of an effective preex isting therap y should not be made for the explicit purpose of 
entering a participant into the study .
Prohibited concomitant medications areoutlined as part of the main ApaRP study in Section 10.6, 
Appendix 6, Prohibited Concomitant Medications . Concomitant therapy  restrictions are outlined 
in Section 10.7, Appendix 7, Restricte d Concomitant Medications.
The sponsor must be notified in advance (or as soon as possible thereafter) of any instances in 
which prohibited therapies are administered.
10.13.9. Discontinuations of study intervention and Participant 
discontinuations/withdrawal
10.13.9.1. Discontinuation of Study Intervention
A participant's sub- study  intervention s must be discontinued if:
The participant withdraws consent to receive sub-study  intervention s
The investigator believes that for safety  reasons or tolerability  reasons (eg,AE) it is in the 
best interest of the participant to discontinue sub-study  intervention s
Noncompliance with sub-study  intervention sadministration
The sub-study  is terminated (Refer to Section 10.13.6.1 , Appendix 13, Overall Design for 
details)
Participants experiencing treatment -related seizure of any grade will have apalutamide 
permanentl y discontinued
If a participant discontinues sub-study intervention sfor any reason before the end of the sub-study , 
then the last scheduled sub-study  assessments should be obtained. If a participant misses doses of 
either sub-study  intervention for ≥3days, the investigator should consult the sponsor regard ing 
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 83
Status: Approved ,  Date: 20 April 2021continuation in the sub-study . If a participant discontinues sub-study  intervention sdue to disease 
progression, the subsequent treatment including radiation will be captured in the eCRF, if known. 
10.13.9.2. Rechallenge
Refer to the main ApaRP study  protocol Section 7.1.1 , Rechallenge for details.
10.13.9.3. Participant Discontinuation/Withdrawal From the Study
A participant will be withdrawn from the sub- study  for any  of the followin g reasons:
• Lost to follow -up
• Withdrawal of consent
• Investigator’s discretion
• Seizure
• Death
When a participant withdraws before sub-study  completion, the reason for withdrawal is to be 
documented in the eCRF and in the source document. If the reason for withdrawal from the 
sub-study  is withdrawal of consent, then no additional assessments are allowed. Refer to main 
ApaRP protocol Section 7.2, Participant Discontinua tion/Withdrawal From the Study and Section 
7.2.1 , Withdrawal From the Use of Research Samples for further details.
10.13.9.4. Lost to Follow -up
To reduce the chances of a participant being deemed lost to follow -up, prior to study  entry, 
attempts should be made to obtain contact information from each participant, eg, home, work, and 
mobile telephone numbers and email addresses for both the participant as well as appropriate 
family members.
Participant swill be considered lost to follow -up if they fail to return for scheduled visits and are
unable to be contacted b y the study  site. A participant cannot be deemed lost to follow -up until all 
reasonable efforts made by the study -sitepersonnel to contact the participant are deemed futile . 
Refer to main ApaRP protocol Section 7.3Lost to Follow -up for further details.
10.13.9.5. National Disaster/Extra Ordinary  Circumstances
Refer to main ApaRP protocol Section 7.4, National Disaster/Extra Ordinary  Circumstances for 
details.
10.13.10. Study Assessments and Procedures
Overview
The sub- study  Schedule of Activities summarizes the frequency and timing of efficacy  and safet y 
measurements applicable to this sub-study . Refer to Section 10.13.3 ,Appendix 13, Schedule of 
Activities for the timing and frequency  of sample collections.
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 84
Status: Approved ,  Date: 20 April 2021Blood collections should be kept as close to the specified time as possible. Actual dates and times 
of assessments will be recorded in the source documentation and eCR F.
The total blood volume for the sub-study  is approximately  30mL.
Repeat of unscheduled samples may  be taken for technical issues with the samples.
Sub-Study -Specific Materials
The investigator will be provided with the following information in addition to what is provided 
as part of the main ApaRP protocol (refer to Section 8, Study -Specific Materials for details):
• ICF sub-study  template
• Sub-study  pilldiary  (foun d inSection 10.14 ,Appendix 14)
10.13.10.1. Efficacy  Assessments
Efficacy  assessments include serum testosterone and will be assessed prior to the first dose of 
relugolix monotherap y(Day  -14), prior to starting apalutamide coadministration (Day  1), and 
following 28 days of apalutamide and relugolix coadministration, per the sub-study  SoA. A 
testosterone level <50 ng/dL  will be considered an indicator of castration.
10.13.10.2. Safety  Assessments
Participants will be monitored for safet y from the beginning of the study  treatment (Day  -14) and 
at each sub-study  visit. Events related to and associated with the recovery  from the pre-planned 
RP will not be collected.
Adverse events will be reported and followed by the investigator as specified in the main ApaRP 
protocol Section 8.3, Adverse Events and Serious Adverse Events and Section 10.4, Appendix 4, 
Adverse Events, Serious Adverse Events, Product Qualit y Complaints, and Other Safet y 
Reporting: Definitions and Procedures for Recording, Evaluating, Follow -up, and Reporting .
Any clinically  relevant changes occurring during the sub-study  must be recorded on the AE section 
of the eCRF.
Any clinicall y significant abnormalities persisting at the end of the sub-study /early  withdrawal 
will be followed by the investiga tor until resolution or until a clinicall y stable condition is reached.
The sub-study  will include the evaluations of safety  and tolerability  included in the main ApaRP 
protocol as noted in Section 8.2.1 , Phy sical Examinations, and 8.2.2 ,Vital Signs.
10.13.10.2.1. Electrocardiograms
A 12 -lead ECG will be conducted at screening, after 14 day s of relugolix monotherapy , and after 
28days of apalutamide and relugolix coadministration, to examine QT prolongation. During the 
collection of ECGs, participants should be in a quiet setting without distractions (eg, television, 
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 85
Status: Approved ,  Date: 20 April 2021cell phones). Participants should rest in a supine position for at least 5 minutes before ECG 
collection and should refrain from talking or moving arms or legs. If blood sampling or vital sign 
measurement is scheduled for the same time point as ECG recording, the procedures should be 
performed in the following order: ECG(s), vital signs, blood draw.
10.13.10.2.2. Adverse Events and Serious A dverse Events
Adverse events will be reported by the participant (or, when appropriate, by a caregiver, surrogate, 
or the participant's legally acceptable representative) for the duration of the sub -study .
For further details on AEs and SAEs (Definitions and Classifications; Attribution Definitions; 
Severity  Criteria; Special Reporting Situations; Procedures) as well as product quality  complaints, 
refer to the main ApaRP protocol Section 8.3, Adverse Events and Serious Adverse Events, 
Section 10.4, Appendix 4, Adverse Events, Serious Adverse Events, Product Quality Complaints, 
and Other Safet y Reporting: Definitions and Procedures for Recording, Evaluating, Follow -up, 
and Reporting.
10.13.11. Statistical Considerations
Statistical analy sis w ill be done b y the sponsor or under the authorit y of the sponsor.
The primary  hypothesis of this sub-study  is that coadministration of apalutamide 240 mg once 
daily  with relugolix 120 mg once daily (following a loading dose of 360 mg) will achieve and 
maintain castrate levels of testosterone (<50 ng/dL ). Clinical decision rule is that if 2 or more 
participants have a testosterone ≥50ng/dL on Day 28, the sub -study  will be considered negative. 
The 95% 1-sided upper limit for the observed incidence of propor tion of patients not able to 
maintain castrate levels is 22.1% if no participant out of 12 hasa testosterone ≥50ng/dL and 33.9% 
if 1 participant out of 12 hasa testosterone ≥50ng/dL. Percentage of participants maintaining 
testosterone <50 ng/dL through Day 28will be summarized descriptively .
Once one cycle (28 days) of the coadministration of apalutamide and relugolix has completed, the 
participants will transition to the treatment schedule of the main ApaRP protocol beginning at 
Cycle 2 Day 1. Safet ydata collected during the coadministration of apalutamide and relugolix will 
be summarized descriptively . Data for participants transitioned to the main ApaRP protocol 
schedule will be summarized at the end of the study  using methods similar to the main protocol 
analysis.
[STUDY_ID_REMOVED]
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 87
Status: Approved ,  Date: 20 April 202116
17
18
19
20
21
22
23
24
25
26
27
28
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 88
Status: Approved ,  Date: 20 April 202110.15. Appendix 15: Protocol A mendment History
The Protocol Amendment Summary  of Changes Table for the current amendment is located 
directly  before the Table of Contents (TOC) .
Amendment 1 (12 August 2020)
Overall Rationale for the Amendment: The main reason for the amendment is to add visit windows, 
administrative changes, and specify the unit for prostate -specific antigen (PSA) level for high risk 
population.
Section number
and Nam eDescription of Change Brief Rationale
1.1 Synopsis Overall 
Design; 4.1 Overall 
Design; 4.4 End of 
Study Definit ionDefinition of end of study (EOS) is updated to:
“The EOS is defined as the date of last 
participant’s enrollment +24 months or 
discontinuation of all study participants from the 
study, whichever occurs first.”Clarified the definition of EOS to 
allow  some participants to have 
follow -up visits beyond 24 months 
from enrollment.
1.1 Synopsis Overall 
Design, Intervention 
Groups and 
Duration; 4.1 
Overall Design; 6.1 
Study Intervention 
AdministrationText is added to define treatment with apalutamide; 
text has been rew orded to define treatment duration 
of 12 cycles for apalutamide.To define treatment cycles and 
treatment duration.
1.1 Synopsis Overall 
Design, Intervention 
Groups and 
Duration; 6.1 Study 
Intervention 
AdministrationText is added to mention the use of study 
intervention (apalutamide) as per its United States 
Package Insert (USPI).Added text to accommodate 
prospective changes in apalutamide 
label.
1.1 Synopsis 
Biomarker 
Evaluations; 8.6 
Biomarkers Text added to specify that full histopatholo gy 
report w ill be sent along with the primary biopsy 
specimen to sponsor’s laboratory partner.To clarify the steps in biomarker 
assessment.
1.3 Schedule of 
Activities (SoA)Updated footnote jto: “Tissue sample to be 
collected from the primary biopsy and sent to 
sponsor’s laboratory partner along with a copy of 
the full histopathology report of the biopsy 
specimen.”
1.2 Schema; 5.1 
Inclusion criteriaFigure 1 and inclusion criterion 5 are up dated to 
include the unit of PSA level as ng/mL.Added the unit of PSA for clarity.
1.3. Schedule of 
Activities (SoA)‘Focused physical examinations including skin 
assessment’ is added at Baseline.Text added t o be consistent with 
Inclusion criteri on4 have recovered 
from radical prostatectomy (RP) 
procedure ,per the clinical 
judgement of the investigator.
1.3. Schedule of 
Activities (SoA)Footnote is updated to add recording of alcohol 
intake directly in the eCRF.Text added to record history of 
alcohol intake directly into the 
eCRF in alignment with lifestyle 
restrictions #1).Appendix 3, 10.3.10 
Source DocumentsText to include history of alcohol intake including 
type, usage, amount, and frequency is added to the 
list of data that will be recorded directly into the 
electronic Case Report Form (eCRF).
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 89
Status: Approved ,  Date: 20 April 2021Section number
and Nam eDescription of Change Brief Rationale
1.3 Schedule of 
Activities (SoA)New  footnotes a and b are added to allow  a visit 
window  of ±7 calendar days for Visits 2 through 8 
and a visit window of ±14 calendar days, Visit 9 
onwards for all follow -up visits. The subsequent 
footnotes are rearranged alphabetically and are 
updated in the SoA.Visit windows are added to allow  
scheduling flexibility.
1.3 Schedule of 
Activities (SoA)New  footnote i added for plasma samples :
“Collected at baseline, 12 m onths or end of 
treatment, and at 24 months or progression 
(whichever comes first) .”Added to clarify the guidance of 
‘whichever comes first’
1.3. Schedule of 
Activities (SoA)New  footnotes kand lare added to start collection 
of concomitant therapi es and adverse events (AEs) 
from the time of first dose of apalutamide.Added the day of commencing 
concomitant therapy and AE 
collection to be consistent 
throughout the protocol and in 
agreement with Global Medical 
Safety (GMS) to collect AEs 
beginning wi th dosing (and not to 
collect AEs that could be associated 
with RP).8.3.1 Time Period 
and Frequency for 
Collecting AE and 
SAE Information; 
Appendix 4, 10.4.1 
AE Definitions and 
ClassificationsReporting of AEs from the time after enrollment is 
changed to Reporting of AEs from the time after 
the participant receives the first dose of 
apalutamide. 
8.3.1 Time Period 
and Frequency for 
Collecting AE and 
SAE InformationText added to mention that A Es will additionally 
be monitored during phone calls with the 
participants. To include all timepoints for AE 
monitoring.
5.2. Exclusion 
CriteriaExclusion criterion 1 is updated to exclude 
presence of soft tissue/bone metastasis or 
metastasis in distant lymph nodes.
Exclusion Criteria 9 is updated w ith “any of the 
following within 6 months prior to baseline” at the 
beginning of the sentence.To clarify the metastasis criterion.
Rearranged the w ording to clarify 
that the 6 months period applies to 
all the conditions listed therein.
7.1. Discontinuation 
of Study 
InterventionText is added to record the subsequent therapy, if 
known, in the eCRF for participants discontinuing 
the study intervention due to disease progression.Added instructions to record 
subsequent therapy.
Deleted the text: “Study intervention assigned to 
the participant who discontinued study intervention 
may not be assigned to another participant.”To disallow  reassignment of study 
intervention as this is not relevant 
for an open -label study.
7.2.1 Withdraw al 
From  the Use of 
Research Samples; 
Appendix 3, 10.3.1 
Regulatory and 
Ethical 
Considerations‘Optional research sample’ is changed to ‘research 
sample’ and the sentences are rew orded 
accordingly.The provision to keep research 
samples optional is deleted as this 
is not considered optional 
collection.
7.2.1 Withdraw al 
From  the Use of 
Research SamplesParagraph on "w ithdrawal from optional research 
samples while remaining in the main study" is 
deleted.The paragraph is not applicable as 
the provision to keep research 
samples optional is deleted.
Provision of separate Informed Consent Form 
(ICF) for optional research is deleted.Separate ICF is not applicable for 
research samples as the details are 
included in the main ICF.
8.3.8 Adverse 
Events of Special 
InterestAdded text:
“For apalutamide, there are no non -serious AEs of 
special interest identified.”To provide background information 
on apalutamide AEs of special 
interest.
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 90
Status: Approved ,  Date: 20 April 2021Section number
and Nam eDescription of Change Brief Rationale
“Rash is an AE of clinical interest” is changed to 
“Rash is an AE of special interest”.Text is modified for consistency 
with the heading.
Appendix 4, 10.4.3 
Severity CriteriaText to grade AEs as per Common Terminology 
Criteria for Adverse Events (CTCAE) version 5.0 
is added.
Text to grade AEs into mild, moderate, and severe 
is deleted.Changed the AE grading criteria to 
be consistent with the standard for 
oncology studies.
Appendix 10, 10.10 
Phone Calls With 
ParticipantsAdded new bullet points to the ‘Guide for 
discussion during phone calls’Added additional bullets for clarity 
on guidance for phone calls.
Throughout protocol Minor grammatical, spelling, and formatting 
changes are made.Minor errors w ere noted.
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 91
Status: Approved ,  Date: 20 April 2021REFERENCES
1. American Red Cross http://www redcrossblood.org/donating -donating blood/e ligibility requirements
2. Bolla M, Collette L, Blank L, et al. Long -term results with immediate androgen suppression and external 
irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. 
Lancet. 2002;360 (9327) :103-106.
3. Chang A J, Autio KA, Roach M, Scher HI . “High -risk” Prostate Cancer: Classification and Therapy. Nat Rev 
Clin. Oncol. 2014;11(6):308 -323.
4. Chi KN, Agarwal N, Bjartell A, et al., Apalutamide for Metastatic, Castration -Sensitive Prostate Cancer . N 
Engl J Med .2019 ;381(1):13 -24.
5. D'Amico A, Attschuler M, Whittington R, Kao G, Malkowicz SB, Wein A. The use of clinical parameters in 
an interactive statistical package to predict pathological features associated w ith local failure after radical 
prosta tectomy for prostate cancer. Clin Perform Qual Health Care .1993 ;1(4):219 -222.
6. Denham JW, Steigler A, Lamb DS, et al. Short- term androgen deprivation and radiotherapy for locally 
advanced prostate cancer: results from the Trans -Tasm an Radiation Oncology Gr oup 96.01 randomised 
controlled trial. Lancet Oncol. 2005;6 (11):841-850.
7. Erleada® Package Insert. Horsham PA: Jans sen Products LP; 2020.
8. Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer -specific mortality following 
biochemical recurrence after radical prostatectomy. JAMA. 2005;294 (4):433-443.
9. Granfors T, Modig H, Damber JE, Tomic R. Combined orchiectomy and external radiotherapy versus 
radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involve ment: a 
prospective randomized study. J Urol. 1998;159 (6):2030-2034.
10. International Council forHarmonisation of Technical Requirements for Registration of Pharmaceuticals for 
Human Use. ICH Harmonized Tripartite Guideline E14: Clinical evaluation of QT/QTc interval prolongation 
and proarrhythmic potential for non -antiarrhythmic drugs. ICH 12 May 2005.
11. Investigator’s Brochure: JNJ -56021927 (apalutamide), Edition 13. Aragon Pharmaceuticals, Inc. ( 01April 
2020).
12. Jemal A, Bray F, Center MM ,Ferlay J, Ward E, F orman D. Global cancer statistics. CA Cancer JClin. 
2011;61(2):69 -90.
13. Kane CJ, Presti JC Jr. Amling CL, et al. Changing nature of high risk patients undergoing radical 
prostatectomy. J Urol. 2007;177 (1):113-117.
14. Martini A,Gangdaglia G, Karnes RJ, et al. Defining the Most Informative Intermediate Clinical Endpoints for 
Predicting Overall Survival in Patients Treated w ith Radical Prostatectomy for High -risk Prostate Cancer. Eur 
Urol Oncol .2019 ;2(4):456 -463.
15. Messing EM , Manola J, Yao J, et al. Immediate versus deferred androgen deprivation treatment in patients 
with node -positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol .
2006 ;7(6):472 -479.
16. Murata Y, Tatsugami K, Yoshikawa M, et al. Predictive factors of biochemica l recurrence after radical 
prostatectomy for high -risk prostate cancer. Int J Urol . 2018 ;25(3):284 -289.
17. National Comprehensive Cancer Netw ork Guidelines for Treatment of Prostate Cancer; Version 4 , 2019; 
September 5, 2019. Accessed October 2019 .
18. New  Drug A pplication (NDA) 214621 Relugolix April 20, 2020.
19. ORGOVYX Package Insert. Brisbane CA :Myovant Sciences INC; 2020.
20. PASS 15 Pow er Analysis and Sample Size Software (2017). NCSS, LLC. Kaysville, Utah, USA. Availab le at 
https://www.ncss.com/software/pass . Accessed November 2019 .
21. Pilepich MV, Winter K, Lawton C, et al. Phase III trial of androgen suppression adjuvant to definitive 
radiotherapy. Long term results of RTOG study 85 -31. Proc Am Soc Clin Oncol. 2003;22:381 (abstr 1530).
[STUDY_ID_REMOVED]
JNJ-56021927 (apalutamide)
Clinical Protocol 56021927PCR2041 Amendment 2
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 92
Status: Approved ,  Date: 20 April 202122. Pound CR, Partin AW, Eisenber ger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression 
after PSA elevation following radical prostatectomy. JAMA . 1999 ;281(17):1591 -1597.
23. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA. 2005;294:238 -244.
24. Shore ND, Saad F, Cookson MS, et al. Oral Relugolix for Androgen -Deprivation Therapy in Advanced 
Prostate Cancer. N Engl J Med. 2020; 382: 2187 -2196.
25. Smith MR, Saad F, Chowdhury S, et al. Apalutamide Treatment and Metastasis -free Survival in Prostate 
Cancer. N Engl J Med .2018 ;378(15): 1408- 1418.
26. Stephenson AJ, Scardino PT, Eastham JA, et al. Preoperative nomogram predicting the 10 -year probability of 
prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst .2006 ;98(10):715 -717.
27. Stephenson AJ, Kattan MW, Eastham JA, et al. Defining Biochemical Recurrence of Prostate Cancer After 
Radical Prostatectomy: A Proposal for a Standardized Definition. J Clin Oncol .2006;24 (24):3973 -3978.
28. Vargas C , Kestin LL, Weed DW, Krauss D, Vicini FA, Martinez AA. Improved biochemical outcome with 
adjuvant radiotherapy after radical prostatectomy for prostate cancer w ith poor pathologic features. Int J Radiat 
Oncol Biol Phys .2005 ;61(3): 714-724.
29. Xie W , Regan MM, Buyse M, et al. Metastasis -Free Surv ival Is a Strong Surrogate of Overall Survival in 
Localized Prostate Cancer. J Clin Oncol .2017 ;35(27):3097 -3104.
30. Xtandi®Package Insert. Northbrook IL:Astellas Pharma US Inc ;2020.
[STUDY_ID_REMOVED]
[STUDY_ID_REMOVED]